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Abstract
Understanding the processes that cause diseases is now one of the hot topics
in biological research. In the past, most of the genetic diseases were associated
to a single gene, but there are a lot of diseases that cannot be explained by the
action of a single gene, and they can only be explained, but by malfunctions of a
set of genes. After human genome was sequenced, it became evident that genes
do not act alone in a cell, but together in an intricate network of relationships
that determine their activity. This discover resulted in the beginning of systems
biology, that aims to understand how cellular components are related to give
rise to life. In systems biology, networks describing the relationships that can
be established between gene are called signaling pathways.
The explosion of new high-throughput technologies has allowed to measure
simultaneously thousands of cellular elements, including gene expression, so
many approaches trying to explain the diﬀerential behavior of these signaling
pathways when comparing control and disease samples by using gene expression
data have appeared in the last years.
In this thesis, a novel methodology is introduced to analyze expression data
in a pathway context. First, signaling pathways were modeled and dissected in
smaller substructures called subpathways, that collect the individual biological
functions included into the pathway. This model has into account the diﬀerent
nature of nodes and edges in the pathway network and evaluates them according
to the underlying biology that they represent. The levels of expression of several
probe sets from diﬀerent microarray platforms were also modeled. Speciﬁcally,
probe set distribution was ﬁtted to a mixture of two distributions (gamma or
normal) associated to the active and inactive state of the probe set. These
distributions were then used to estimate the probability of a probe set to be
active in a given sample. The estimated probability of activation was ﬁrst
summarized to node activation probability and then was propagated along the
subpathways, by having into account the diﬀerent types of edges that relate the
nodes; this results in an estimation of the activity of each subpathway. Given
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a control-case experiment, the proposed approach estimates the activity of
each subpathway in each sample, and compare then to obtain the subpathways
signiﬁcantly activated/deactivated between both conditions.
This method overcomes most of the limitations of previous methods and
provides the research community with a user-friendly web-tool to analyze ex-
pression data from a control-disease experiment in a signaling pathway context.
It is very useful for an easy interpretation of the results in terms of gain/loss
of biological functions. Thus, with this strategy, it is possible to understand
the mechanisms driving a disease in terms of systems biology, since we ob-
tain a comprehensive path of genes, closely related, that produce a determined
function in the cell, instead of a single gene or a set of genes without relation
between them.
Resumen
Hoy en día, uno de los temas más candentes en la investigación biomédica
es entender los procesos que producen enfermedades. En el pasado, la mayor
parte las enfermedades génicas fueron asociadas al mal funcionamiento de un
solo gen, pero hay muchas enfermedades que sólo pueden ser explicadas por el
mal funcionamiento de un conjunto de genes. Una vez el genoma humano fue
secuenciado, se hizo evidente que los genes no actúan solos en la célula, si no
que están unidos por una intrincada red de interacciones que determinan su ac-
tividad. Este descubrimiento dio lugar al inicio de la biología de sistemas, que
trata de entender cómo los componentes celulares se relacionan entre ellos para
dar lugar a la vida. En biología de sistemas, las redes que describen las rela-
ciones que se establecen entre genes se llaman rutas de señalización. Por otra
parte, el auge de nuevas tecnologías de alto rendimiento, ha permitido en los úl-
timos años medir simultáneamente miles de componentes celulares, incluyendo
la expresión génica. Esto ha producido la creación de nuevas metodologías
para el estudio del comportamiento diferencial de las rutas de señalización
entre dos condiciones experimentales dados los niveles de expresión de cada
uno de los genes contenidos en la ruta. En esta tesis, presentamos una nueva
metodología para analizar los datos de expresión en el contexto de las rutas
de señalización. Primero, las rutas de señalización fueron modeladas y dividi-
das en subestructuras más pequeñas, que llamaremos subrutas, que recogen las
diferentes funciones biológicas individuales incluidas en la ruta completa. Este
modelado tiene en cuenta la diferente naturaleza tanto de los nodos como de
las aristas que forman la red, permitiendo que sean evaluadas de acuerdo con el
concepto biológico que representan. Además, se modelaron las distribuciones
de niveles de expresión de las sondas de diversos chips the expresión génica.
Concretamente, la distribución de cada sonda fue ajustada a una mixtura de
distribuciones (gamma o normal) asociadas con los estados activo e inactivo
de la sonda, respectivamente. Estas distribuciones fueron usadas para estimar
la probabilidad de que una sonda esté activa en una determinada muestra. La
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probabilidad de activación estimada fue propagada a continuación a lo largo
de las subrutas, teniendo en cuenta las diferentes relaciones que se pueden es-
tablecer entre los nodos, obteniendo una estimación de la actividad de cada
una de las subrutas. Por lo tanto, dado un experimento que compara dos
condiciones biológicas, la metodología propuesta estima la actividad de cada
una de las subrutas, y las compara para obtener las subrutas signiﬁcativamente
activas o inhibidas entre ambas condiciones. Esta metodología supera la mayor
parte de las limitaciones presentadas por los métodos anteriores y proporciona
a la comunidad cientíﬁca una herramienta web de fácil manejo que permite
analizar los datos de expresión obtenidos en un experimento comparando dos
condiciones dentro del contexto de las rutas de señalización. En consecuen-
cia, la estrategia propuesta en esta tesis nos permite entender los mecanismos
que dan lugar a una enfermedad en términos de la biología de sistemas, ya
que permite obtener como resultado de nuestro análisis un conjunto de genes,
biológicamente relacionados y que conjuntamente producen una determinada
función génica, en vez de un gene o conjunto de genes sin ninguna relación
entre ellos.
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1Chapter
Introduction
"Begin at the beginning," the King said gravely, "and go
on till you come to the end: then stop."
 Lewis Carroll, Alice in Wonderland
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2 CHAPTER 1. INTRODUCTION
1.1 Molecular biology
Biology can be seen as a counterpoint between two diﬀerent elements: individ-
ual variability and the constancy of fundamental mechanisms. The divergence
of life created a huge variety of living forms, but the fundamental mechanisms
were conserved in the evolutionary process. Therefore, studying these mecha-
nisms essential to understanding the reasons for the diﬀerences and similarities
between living things.
One of the lowest levels of organization in living organisms is the cell. Uni-
cellular organisms are formed by one single cell, while multicellular organisms
are comprise groups of cells performing specialized functions and are linked
by intricate communication systems. Strikingly, all the information needed to
generate the molecules that perform cellular functions, is stored in the form of
double-stranded deoxyribonucleic acid (DNA) molecules. DNA is the prereq-
uisite for the inception of all higher life forms for two main reasons: ﬁrst, it
allows species to pass traits from parents to their oﬀspring, thus producing in-
dividuals with the same characteristics, and second, it controls the production
of the diﬀerent proteins that perform most of the function of the cells.
The structure of DNA was discovered by the researchers James Watson and
Francis Crick en 1953[1], who jointly received the Nobel Prize in Physiology or
Medicine in 1962 for their discovered. It consists of long unbranched, paired
polymer chains, formed by four types of monomers, called nucleotides which
are named depending on the base that forms them: Adenine (A), Guanine
(G), Cytosine (C) and Thymine (T). The doubled-stranded structure of the
DNA molecule is organized according base complementation: A binds to T,
and C binds to G. The complete set of information carried by an organism
in its complete DNA sequence is called the genome and it carries information
about all the proteins that an organism will ever synthesize. A huge amount of
information is contained in the genome is astonishing, for example, using the
four-letter nucleotide alphabet, the nucleotide sequence for a small gene can
take up a page of text, and the whole human genome would ﬁll thousands of
books.
The discovery of DNA, which was not originally recognized for the break-
through it was, allows researches to understand the relationship between DNA
and the ﬁnal protein product that performs determined processes in the cell.
This process was described by Crick in 1970 (Figure 1.1) in the Central Dogma
of Molecular Biology [2]. This dogma describes a two-step process, known
as gene expression. First, DNA is transcribed into ribonucleic acid (RNA)
molecules and then, RNA is translated into proteins. This description is ex-
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tremely simplistic, but serves as a very useful for understanding the ﬂow of
information in biological systems. The details of the process have been elabo-
rated by later discoveries which introduce regulatory components and changes
in the ﬂows of information. Here only the modiﬁcations which are necessary
for understanding this thesis will be introduced1.
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Figure 1.1: Central Dogma of Molecular Biology. Information encoded
in deoxyribonucleic acid (DNA) is used to synthesize ribonucleic acid (RNA)
molecules in a process called transcription. These RNA molecules then mediate
protein synthesis in a process termed translation. The information contained
in DNA molecules can also be used to generate other DNA molecules in the
process of DNA replication
In the ﬁrst step in the Central Dogma of Molecular Biology, called transcrip-
tion, DNA is transcribed into RNA molecules. DNA molecules are usually very
large and contain the speciﬁcations for thousands of proteins; it is not tran-
scribed as a whole, rather, individual segments of the entire DNA sequence
1For more details see [3]
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are transcribed into separate molecules, each one is translating into diﬀerent
proteins. Each DNA segment that encodes a protein is known as a gene: dur-
ing transcription, genes are used as a template to synthesize shorter molecules
RNA polymers. These molecules are very closely related to DNA, except for
two characteristics: RNA is a single-stranded molecule, and Uracil (U) substi-
tute the Thymine (T) base.
In second step, called translation, RNA molecules direct the synthesis of an-
other type of polymers: proteins. Protein molecules, are also long, unbranched
polymer chains formed by monomers. However, protein monomers are diﬀerent
from those comprising DNA and RNA. In the translation process, information
encoded in the RNA sequence is read out in groups of three nucleotides at a
time, each nucleotides triplet (codon) speciﬁes a single amino acid in the re-
sulting protein. There are 64 (=4x4x4) possible triplet combinations, and all
of them occur in nature, but several codons correspond to the same amino acid
(see Table 1.1); there are 20 types of amino acids.
2nd position
1st U C A G 3rd
UUU
}
Phe
UCU
Ser
UAU
}
Tyr
UGU
}
Cys
U
U UUC UCC UAC UGC C
UUA
}
Leu
UCA UAA
}
Stop
UGA Stop A
UUG UCG UAG UGG Trp G
CUU
Leu
CCU
Pro
CAU
}
His
CGU
Arg
U
C CUC CCC CAC CGC C
CUA CCA CAA
}
Gln
CGA A
CUG CCG CAG CGG G
AUU
Ile
ACU
Thr
AAU
}
Asn
AGU
}
Ser
U
A AUC ACC AAC AGC C
AUA ACA AAA
}
Lys
AGA
}
Arg
A
AUG Met ACG AAG AGG G
GUU
Val
GCU
Ala
GAU
}
Asp
GGU
Gly
U
G GUC GCC GAC GGC C
GUA GCA GAA
}
Glu
GGA A
GUG GCG GAG GGG G
Table 1.1: Nucleotide triplet to aminoacid conversion table. Depend-
ing on the position of the nucleotides in the triplet, diﬀerent aminoacids are
synthesized. (The abbreviations of the aminoacid name are shown in the ab-
breviations section).
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One of the most relevant modiﬁcations of the Central Dogma of Molec-
ular Biology came with the discovery of RNA splicing. In 1977, Sambrook
discovered that genes are composed of two types of regions called introns and
exons[4]. Exons are regions of DNA that code for a protein, while introns do
not code for any speciﬁc protein and are spliced out of RNA molecules before
they are translated, giving rise to a ﬁnal messenger RNA (mRNA), which only
contain information from coding exonic regions. This process is referred as
RNA splicing (Figure 1.2a). In 1978, Gilbert described the alternative splicing
process of transcription in which introns are dismissed and exons are combined
in diﬀerent ways in order to produce diﬀerent proteins. That is, one gene
can synthesize several diﬀerent proteins by combining diﬀerent exon, and each
combination produces a protein called a transcript. Therefore, a gene can be
translated into several transcripts that encode diﬀerent proteins (Figure 1.2b).
  
Exon1 Exon3Exon2 Exon4Intron1 Intron2 Int.3
Exon1 Exon3Exon2 Exon4Intron1 Intron2 Int.3
Transcription
(RNA synthesis)
DNA
Gene
Nuclear RNA
mRNA
RNA splicing
Exon1 Exon3Exon2 Exon4
(a) RNA splicing
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mRNA
Alternative splicing
Protein 1 Protein 2
Translation
(b) Alternative splicing
Figure 1.2: (a) RNA splicing. A gene is formed by exons (coding regions of
DNA) and introns (non-coding DNA regions) . Each gene is transcribed in its
entirety into nuclear RNA and then the RNA splicing process discards the in-
tron regions to form mRNA comprising only coding regions. (b) Alternative
splicing. After RNA splicing, alternative splicing combines diﬀerent exons to
produce diﬀerent transcripts that leads to the synthesis of diﬀerent proteins.
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1.2 Gene expression
Gene expression is the primary mechanism by which the genotype (hereditary
information contained in the DNA) gives rise to the phenotype (genotype ex-
pression modiﬁed by the environment). Gene expression is an interpretation
of the genetic code, in the sense that the properties of the products of gene
expression lead to the organism's phenotype.
Gene expression can be measured at diﬀerent levels (usually at the mRNA or
protein levels), corresponding with both steps of the Central Dogma of Molecu-
lar Biology (Figure 1.1). It is currently cheaper, and more precise and compre-
hensive to measure mRNA levels and this have the added beneﬁt of compati-
bility with the use of high-throughput techniques for measuring thousands of
genes in a single run. Even though mRNA is sometimes not the ultimate prod-
uct of a gene, and correlation between mRNA and protein levels is not always
straightforward[5, 6], most approaches use mRNA measurements as reasonably
accurate proxies for protein behavior[7]. Speciﬁcally, most of them use diﬀer-
ential expression to compare the abundance of mRNA produced by cells in two
or more diﬀerent conditions.
The way in which mRNA levels are measured has evolved since its begin-
nings in the 70s when the northern blot technique was ﬁrst developed by Alwine
and colleges[8]. Northern blotting is a technique for measuring gene expression
by detecting RNA (or isolated mRNA) in a sample[8]. This technique allows
gene expression to be measured in diﬀerent conditions, tissues, or disease states
and compared with a control, but it only allows one or a small number of genes
to be measured at once.
In the 80s, Kary Mullis developed a revolutionary method called PCR (poly-
merase chain reaction)[9] which superceded northen blotting and for which he
received the Nobel Prize for Chemistry in 1994. This technique allowed re-
searches to amplify any selected piece of DNA by several orders of magnitude,
to generate thousands to millions of copies of a particular DNA sequence. Based
on this technique, several methods for measuring gene expression were devel-
oped including reverse transcription PCR (RT-PCR), quantitative PCR, real
time PCR and real time qRT-PCR (real time quantitative reverse transcription
PCR). These techniques are highly quantitative and sensitive, and are generally
used for interrogating a small number of genes in a large number of samples.
Later, in the 90s, high density oligonucleotide microarray technology was
developed to allow the simultaneous measurement of thousands of genes. These
microarrays are formed by thousand of spots, each containing short DNA se-
quences known as probes, which are complementary to the target sequence of
1.2. GENE EXPRESSION 7
interest. This technology is based on the capacity of nucleotides to speciﬁcally
pair with their complementary base. Target probes (in the sample) are ﬂuo-
rescence labeled with, and then hybridized with probes in the microarray. The
higher the number of target probes the more intense the ﬂuorescence signal is,
which consequently, serves as a proxy for the expression level of the probe. Sev-
eral companies have developed microarrays for monitoring known genes from
a genomic point of view.
More recently, the increased use and decreased price of high-throughput
sequencing technologies has allowed steady-state RNA in samples to be se-
quenced. This technique, known as RNA-seq, is "unbiased" (free of depen-
dency on prior knowledge of the sequence of the organism), making it ideal for
discovery, but it remains costly and diﬃcult computationally speaking. Several
comparisons of RNA-seq and microarray measurements have been performed,
which have shown that there is strong agreement between both data sets [10].
Even though RNA-seq is more sensitive, microarrays continue to be far more
successful in many biological settings[11].
1.2.1 Aﬀymetrix DNA microarray gene expression data
DNAmicroarray gene expression technology is widely used and there are several
companies developing diﬀerent chips for monitoring every known gene from a
genomic point of view. Aﬀymetrix GeneChip arrays[12] are the most popular
and they are used by thousands of researchers around the world2.
A DNA microarray is a collection of DNA spots attached to a solid surface.
Each DNA spot contains picomoles of speciﬁc short DNA sequences known as
probes. In the case of Aﬀymetrix technology these probes are oligonucleotides
(short sequences of nucleotides) which are 25 bp long. Any mRNA molecule of
interest (related to a gene) is represented by several probe sets, each of them
comprising 16-20 probe pairs. Each probe pair is composed of a perfect match
(PM) probe and a mismatch (MM) probe. The PM probe represents a section
of the mRNA molecule of interest and the MM probe is created by changing
the middle (13th) nucleotide of the PM probe sequence3 (Figure 1.3).
Each microarray is formed by millions of spots, each of them containing
many copies of a speciﬁc DNA sequence (Figure 1.4b). To measure gene ex-
pression in a sample, the RNA in the cell sample is extracted and all the target
probes in the sample are marked with a ﬂuorescence dye and hybridized onto
2A simple search in PubMed www.ncbi.nlm.nih.gov/pubmed returns more than 7,000
papers citing this technology
3This is done to measure non-speciﬁc binding
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Probe
set
5' 3'
mRNA reference 
sequence
ATCCGTAGACAGTTAGAGTAGATAGCGCTAGACAGATTT
CTGTCAATCTCATCTATCGCGATCT
CTGTCAATCTCAACTATCGCGATCT
perfect match
mismatch
Figure 1.3: Aﬀymetrix probe set Several probes are selected from a mRNA
reference sequence to represent the gene. These probes are paired: there is
a perfect match sequence as well as a mismatch sequence in which only the
central nucleotide diﬀers.
the array (Figure 1.4c). After scanning the array, intensity values PMij and
MMij are recorded for arrays (i = 1, ..., I) and probe pairs (j = 1, ..., J) for
any given probe sets in the array. The highest intensity value represents the
most expressed probe sequence in the sample (Figure 1.4d).
The intensities of the spots represents the degree of hybridization for each
oligonucleotide probe. However, systematic biases are included in expression
level measurements for several reasons, for instance the inclusion of unequal
quantities of RNA or diﬀerences in the labeling or detection eﬃciencies between
the ﬂuorescent dyes[13]. Therefore, the ﬂuorescence intensity of each spot
must be normalized by adjusting individual hybridization intensities before
meaningful biological comparisons. The intensities of the 16-20 probe pair
sets also have to be summarized into a single value in order to deﬁne a single
expression measurement that represents the amounts of mRNA for each probe
set; there exist many methods to do this, the most common of which are
described below.
The intensities of each probe pair are deﬁned as[14]:
PMijn and MMijn, i = 1, ..., I; j = 1, ..., J ;n = 1, ..., N
where: n represents the diﬀerent genes, i the RNA samples and j the probe
pair number.
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Figure 1.4: Aﬀymetrix microarray functioning (a) An Aﬀymetrix mi-
croarray. (b) A microarray can contain thousands of spots, each of them
contains many copies of a particular DNA sequence corresponding to a probe.
(c) An RNA sample is extracted from the cell, labeled with a ﬂuorescent dye,
and hybridized with the complementary sequence. (d) Dyes are illuminated
using ﬂuorescent light to show which RNA fragments hybridized to in which
microarray spots, and consequently which probes are active in the cell.
The four commonly-used summary density measurements are:
Aﬀymetrix's average diﬀerence (AvDiff) This is the Aﬀymetrix default.
It is a trimmed mean deﬁned as:
AvDiff =
1
#A
∑
j∈A
(PMj −MMj)
where A the subset of probes for which dj = PMj−MMj are within three
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standard deviations of the average of d(2), .., d(J−1). This measurement
has some limitations: MM > PM in about one third of the probes and
the linear scale measurement is not optimal for this type of data.
Multiplicative model-based expression index (dChip) The dChip[15] is
deﬁned as the maximum likelihood estimates at the θi, i = 1, ..., I ob-
tained from ﬁtting the following model:
PMij −MMij = θiφj + ij
where: φj represents probe-speciﬁc aﬃnities. Also, the noise compo-
nent is assumed to have independent normally distributed errors (ij ∼
N(0, σ2)).
MAS 5.0 signal This robust average measurement was developed by Hubbell[16]
and is deﬁned as:
signal = TukeyBiweight(log(PMj − CTj))
where CTj is a "repaired" version of MM deﬁned as:
CTj =
{
MMj if MMj < PMj
less than PMj if MMj ≥ PMj
Robust Multi-array Average (RMA) This methodology, developed by Izarry[14],
describes a process in which raw intensity values are background cor-
rected, log2 transformed and quantile normalized. A linear model is
then used to ﬁt normalized data and to obtain an expression measure-
ment for each probe set on each array. This method assumes that n, the
background-adjusted, log2 transformed and normalized PM intensities
(Y ) follow a linear additive model for each probe set:
Yijn = µin + αjn + ijn, i = 1, ..., I; j = 1, ..., J ;n = 1, ..., N
where µin represents the log scale expression level for array i (and there-
fore its estimates give the expression measurements for probe set n on
array j), αjn represents the probe aﬃnity eﬀect
4 and ijn represents an
independent identically distributed error term with a mean of zero. A
robust linear ﬁtting procedure was used to estimate µin and the resulting
summary statistic is referred to as RMA. It presents some advantages
regarding the other deﬁned measurements[14]:
4It is assumed that
∑
j αj = 0 as Aﬀymetrix technology has chosen probes with intensities
that on average are representative of the associated gene expression
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1. Better precision, in particular for lower expression values.
2. It provides more consistent estimates of fold-change.
3. Higher speciﬁcity and sensitivity when using fold-change analysis.
1.2.2 Gene status from gene expression
Identifying which state a gene or probe set is in is a problem broadly studied
in biology. Classiﬁcation of genes in alternative states is a simpliﬁcation of
more complex patterns of gene behavior and action. Nevertheless, empirical
evaluation of the observed data ﬁnds that gene expression patterns commonly
ﬁt one of two alternative expression level distribution states: present/absent
(up/down). However, this classiﬁcation is not easy since the range of expression
of each gene and its activation/deactivation threshold can be extremely variable
(Figure 1.5).
A expression array experiment result is a Present/Absent call [17] related to
the MAS 5.0 measurement. This is based on a hypothesis test using PM and
MM intensities. It supposes that theMM intensities are accurate estimates of
a genes' speciﬁc background and it uses Wilcoxon signed-rank test?? to declare
if a gene is present or not. The decision rule is based upon the resulting p-
values:  if p < α1 Present (P)if α1 < p < α2 Marginally present (M)
if p > α2 Absent (A)
This approach, is often used to ﬁlter false positives from a large collection
of probes on an expression array. But it has three principal disadvantages[18]:
1. It does not provide the user with a statistical gauge of the basic claim
behind the Present/Absent call
2. It does not compare calls across multiple samples
3. It cannot beneﬁt from the increasingly sophisticated techniques for ad-
justing gene expression reading because it cannot operate on adjustable
readings.
These limitations were overcome by Efroni[7] who developed a method to
calculate the probability of each gene belonging to each state, a methodology
which the same authors[18] better explained by using quantitative expression
level readings to build a statistical expression model for each probe set, based
12 CHAPTER 1. INTRODUCTION
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Figure 1.5: Distribution of the expression of 100 random probe sets.
A diﬀerent range of expression for each probe set can be observed. Short and
long ranges of expression and high and low levels of expression can be seen,
depending on the probe set.
on an assumed bimodal gene expression distribution that can be captured by
mixed gamma distributions. This bimodal distribution is chosen after applying
the Bayesian Information Criterion (BIC)[19]. The best ﬁt is obtained with
two distributions that account for the two states of an expressed gene: Up
1.3. BIOINFORMATICS AND SYSTEMS BIOLOGY 13
and Down[7]. Therefore, data points can be used, for each single probe set, to
infer a mixture of two gamma distributions, one distribution representing the
Down state and another one representing the Up state. Once, these models are
built for each probe set on the array and are given a new expression value, the
probability of the new value belonging to each distribution can be estimated.
1.3 Bioinformatics and systems biology
Over the past few decades, advances in genomic technologies have produced
explosive growth in the generation of biological data, which has also led to
an unprecedented requirement for databases to store, organize, analyze and
index the data, besides the fact that specialized tools are required to view and
organize the data. This has resulted in new collaborations between computer
scientists, statisticians, mathematicians, and engineers in order to process bi-
ological data, leading to the emergence of the ﬁeld of bioinformatics, whose
principal aims are[20]:
• To organize data in a way that allows researchers to access existing in-
formation and submit new entries.
• To develop tools and resources to analyze this of biological data.
• To use the tools developed to analyze data and interpret the results in a
biologically meaningful manner.
Bioinformatics applications can be classiﬁed into three groups: sequence
analysis, functional analysis, and structural analysis (Table 1.2). The creation
of genomic projects focused on describing gene and protein functions and in-
teractions caused the emergence of functional analysis as major ﬁeld in the
application of Bioinformatics. In this ﬁeld there are a huge number of expres-
sion analysis datasets available in several conditions to the research community
for several conditions, making it easier to discern how gene expression patterns
change as a consequence of physiological cues and disease. The application
of this knowledge applied to ﬁelds such as medicine or pharmacology allows
both the causes of diseases and the development of drugs to treat them to
be better understood. However, it will only be possible to analyze the gene
expression proﬁle of speciﬁc patients with a view to developing personalized
drug for speciﬁcally for them when the price of this technology becomes more
aﬀordable.
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Analysis Description Applications
Sequence
Analytical methods to
understand the features,
function, structure, or
evolution of proteins, RNA
and DNA.
Genome Annotation
Comparative Genomics
Genetics of Disease
Oncogenomics
Phylogeny
Gene & Promoter Prediction
Functional
Analysis of the function and
prediction of the functional
interaction between various
proteins or genes.
Gene expression studies
Analysis of regulation processes
Pathway modeling
Protein interaction prediction
Protein proﬁling
Systems biology
Structure
Analysis and prediction of
the three-dimensional
structure and roles of
macromolecules such
proteins, RNA, and DNA.
Nucleic acid structure prediction
Protein structure prediction
Protein structure classiﬁcation
Protein structure comparison
Table 1.2: Subﬁelds in bioinformatics
An emergent topic of functional analysis is known as Systems biology, which
focuses on the complex interactions between genes and proteins within biolog-
ical systems. Once the complete human genome sequence became known by
Collins[21] and Venter[22],and genes and proteins were ﬁrst listed, it became
evident that the complexity of the human organism cannot be solely explained
by the number of genes. Thus, the scientist started to ask questions about
the gene interactions that could allow all the diﬀerent diﬀerent complex cell
functions to be performed. This gave rise to the identiﬁcation of an intricate
network of relationships that determine their activity[23], including nodes rep-
resenting molecules (genes, proteins, or diﬀerent types of RNA) or metabolites
(e.g sugars or lipids) and edges representing interactions between them.
Diﬀerent types of biological networks exit, depending on the types of nodes
and edges described by them. Two main classes can be established based on
the interactions that they represent: genetic networks, which account for ge-
netic linkages among genes, and physical networks, which account for physical,
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functional, or regulatory relationships. Centering on physical networks, we can
distinguish three main types of networks depending on the data they represent:
Gene regulatory networks They represent transcriptional and post-transcriptional
gene expression regulation as a collection of elements which interact with
each other indirectly to govern mRNA and protein expression levels.
Protein-protein interaction networks They represent protein-protein in-
teractions, that is, two or more proteins which bind together, often to
carry out their biological function.
Pathway networks They represents a series of actions among molecules in a
cell that leads to production of a certain product or a cellular change. A
pathway can trigger the assembly of new molecules, such as a fat or pro-
tein. Biological pathways can be divided into two main groups: metabolic
pathways and signaling pathways. Metabolic pathways are series of chem-
ical reactions occurring within a cell. Its main components are enzymes
and metabolites. In a metabolic pathway a metabolite is converted into
another metabolite in a series of chemical reactions catalyzed by enzymes.
Signaling pathways are an entire set of cell changes induced by receptor
activation. They are composed by genes and compounds (metabolites).
Cell signaling is part of a complex system of communication that governs
basic cellular activities and coordinates cell actions. In a signaling path-
way the signal is transmitted from a stimulus gene to a receptor gene by
activating or deactivating intermediate genes. This receptor gene syn-
thesizes a certain protein that performs a predetermined function in the
cell.
1.4 Data Repositories
One of the aims of bioinformatics is organize data in a way that allows re-
searchers to access existing information and to submit new entries. Biological
databases are libraries of life sciences information, collected from scientiﬁc ex-
periments, published literature, high-throughput experiment technology, and
computational analyses [24]. There are diﬀerent types of databases depending
on the information they contain (Table 1.3), but they all all share the following
characteristics:
• They handle and share large volumes of biological data.
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• They support large-scale analysis eﬀorts.
• They make data accessible and updated.
• They link the knowledge obtained from various ﬁelds.
Database Type of information
Bibliographic Literature
Taxonomic Classiﬁcation of species
Genomic Gene level information
Protein Protein level information
Public data Experimental data and results
Pathways Metabolic and signaling pathways
Regulation Transcription factors and events
PPIs Protein-protein interactions
Table 1.3: Biological databases classiﬁcation. Classiﬁcation of databases
according of the type of information they contained.
The databases used in the development of this thesis are described below.
The ﬁrst one is a repository of public data, Gene Expression Omnibus Database
(GEO), where data used for analyses were downloaded. The second one is a
pathway database, Kyoto Encyclopedia of Genes and Genomes (KEGG), from
where information about pathways were extracted.
1.4.1 Gene Expression Omnibus database
The Gene Expression Omnibus (GEO) database is a public functional-genomics
data repository from the NCBI (National Center for Biotechnical Information)
[25, 26] that archives and freely distributes microarray, next-generation se-
quencing and other forms of high-throughput functional genomic data submit-
ted by the scientiﬁc community. Tools are provided to help users query and
download experiments and curated gene expression proﬁles. The three main
goals of GEO are to:
• Provide a robust, versatile database in which high-throughput functional
genomic data can be eﬃciently stored.
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• Oﬀer simple submission procedures and formats that support complete
and well-annotated data deposits from the research community.
• Provide user-friendly mechanisms that allow users to query, locate, review
and download studies and gene expression proﬁles of interest.
GEO is now one of the most populars databases for sharing experimental data
with the research community and stores more than one million samples which
are available for free. GEO information is organized in various levels. Samples
(individual data) are linked together by series, that relate them to provide a fo-
cal point for the whole study. Series are grouped into datasets, that represent a
a curated collection of biologically and statistically comparable samples/series.
Finally, platforms represent the diﬀerent technologies which the data comes
from (Table 1.4)
Entity Number of entries
Datasets 3,848
Series 52,901
Platforms 16,661
Samples 1,291,142
Table 1.4: Some numbers in the Gene Expression Omnibus (GEO)
database. This table shows the number of entries at the diﬀerent levels of the
database's organization (December, 2014)
1.4.2 Pathway databases
The Kyoto encyclopedia of Genes and Genomes (KEGG)[27, 28] is a database
resource used to understand the high-level functions and utilities of biologi-
cal systems, such as a cell, an organism, or an ecosystem, from genomic and
molecular-level information. It integrates sixteen main databases in four cate-
gories (Table 1.5)
The information contained in the PATHWAY database is classiﬁed into
seven groups: Metabolism, Genetic Information Processing, Enviromental In-
formation Processing, Cellular Processes, Organismal Systems, Human Dis-
eases, and Drug Development. This database includes general maps built us-
ing orthologs of genes as well as speciﬁc maps for each species, built jointly
with a general map of metabolism. An example of a pathway map in KEGG
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Category Database Entries
System Information
PATHWAY 467
BRITE 158
MODULE 632
Genomic information
ORTHOLOGY 18,307
GENOME 3,510
GENES 15,268,099
SSDB 78,327,335,280
Chemical information
COMPOUND 17,339
GLYCAN 10,987
REACTION 9,776
RPAIR 14,849
RCLASS 2,945
ENZYME 6,415
Health information
DRUG 10,118
DISEASE 1,402
ENVIRON 849
Table 1.5: The Kyoto encyclopedia of Genes and Genomes (KEGG)
database. The databases categories and the number of KEGG entries in each
of them are shown. (December,2014)
database is shown in Figure 1.6. Diﬀerent nodes representing molecules and the
diﬀerent relationships between them are represented. Other databases which
include larger amounts of curated data also exist, but KEGG is now the most
used because it include a large number of processes and species (Table 1.5).
1.5 Pathway Analysis
Pathway analysis is now the ﬁrst choice for the analysis of high-throughput
data[29]. It allows insights into the underlying biology of diﬀerentially ex-
pressed genes to be gained, reduces complexity, and has an increased explana-
tory power.
Pathway analysis is understood as the set of approaches that identify path-
ways aﬀected by a condition, correlating information about pathway knowledge
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Figure 1.6: KEGG maps example. Reference pathway for WNT signaling
in the KEGG database
with gene expression patterns. These approaches can be divided into three prin-
cipal groups or generations according the type of analysis they perform[29].
First generation of methods are known as Over-Representation Analysis
(ORA) approaches (competitive in other review papers[30]). Given a list of
genes selected by a certain criteria, ORA approaches test if each selected path-
way is enriched (over- or under-represented) by genes in the initial list. These
methods are broadly used and several approaches following this philosophy ex-
ist. Nevertheless, this class of methods presents some limitations. Typically,
the gene input list, which is necessary for these approaches, comes from a dif-
ferential expression experiment where genes with p-values under a determined
threshold are selected. Therefore, the results obtained are dependent of the
chosen threshold which causes a loss of information because marginally less
signiﬁcant genes are missed. In addition, these approaches treat all genes in
the list equally. Finally, these methods assume independence between path-
ways, even though they are interconnected because the limits of each pathway
are determined only by the pathway database considered.
A new class of methods were developed to deal with most of ORA limita-
tions. This second generation is referred to as Functional Class Scoring (FCS)
approaches (self-contained methods in other review papers[30]). Given a list
20 CHAPTER 1. INTRODUCTION
of genes and their associated p-values (which come from a gene-level statistical
test), FDR methods compute a running enrichment score for gene grouping.
They are based on global and multivariate approaches that deﬁne a model on
the whole gene set. This approaches are not dependent on any threshold and
consider coordinate changes in gene expression, thus addressing the limitations
of ORA methods. Nevertheless, these methods consider independence between
pathways as ORA methods do. Also, they use changes in expression to rank
genes according a given test, but they do not take into account the magnitude
of the diﬀerence between genes belonging to the same class.
Finally, third generation include Pathway Topology (PT)-Based approaches.
They are very similar to FCS methods, but take pathway topology (relation-
ships between genes or proteins) into account to compute gene-level statistics.
That is, they take advantage of the information available about relationships
between genes that is included in pathway databases. These methods provide a
impact factor (IF) measurement which considers the structure and dynamics of
the pathway by incorporating; biological factors as diﬀerential expression mea-
surements; and by considering the types of interactions; and the gene positions
in the pathway network.
It has been argued that gene networks contain active subpathways (sub-
structures in the pathway network) which are more relevant to gene expression,
than all the pathway members taken together[31]. A new type of methods has
recently emerged which is based on this idea. These methods use pathway
topology in a similar way to PT-Based approaches, but the topology is not
used to obtain a measurement of the behavior of the whole pathway, rather, it
is used to dissect the pathway into subpathways. The ﬁnal output these meth-
ods is an impact factor(IF) for each subpathway in a pathway; we will refer to
these methods as Subpathway-based approaches (SP-based approaches). The
ﬁrst of these subpathway concept methods was SubpathwayMiner[32]. This
method centers on the study of subpathways in the context of metabolic path-
ways. A subpathway is deﬁned as a set of genes in which the distance between
enzymes is less than a parameter called k (user-deﬁned distance). To do this,
each metabolic pathway is converted into an undirected graph with enzymes
and nodes reducing the subpathway mining problem to a sub-graph mining
problem. A p-value, based on hyper-geometric distribution, is then calculated
to evaluate the signiﬁcance of the enrichment for each structure (whole pathway
or subpathway). This p-value takes the total number of genes on the genome,
in the pathway, and the number of diﬀerentially expressed genes on the genome
and in the pathway into account .
Other approaches based on subpathways have recently appeared. SP-Based
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approaches agree than a subpathway is a subset of interconnected nodes in a
pathway network, but two diﬀerent subpathway concepts appear in the scien-
tiﬁc literature. A subpathway can be considered as a subgraph or clique of the
pathway graph, that is, a set of interconnected nodes, or it can be deﬁned as an
individual or linear path from a start-point (node without parent nodes) and
an end-point (node without descendant nodes). Subpathway-based approaches
can be divided in two groups based on this separation:
Clique based. There are two main approaches in this group: DEGraph[33]
which is implemented as an R-package, and clipper[34] which is imple-
mented as an R-package and as a web-tool called GraphiteWeb[35]. Both
deﬁne subpathways as sets of interconnected genes. They also evaluate
if diﬀerential expression pattern of genes in the subpathway agree with
the diﬀerent activations/inhibitions that are established between these
genes. More speciﬁcally, DEGraph represents the pathway by a graph and
a mean shift (vector of diﬀerences in the mean expression of all the genes
in the pathway between two populations of interest); when the shift is
coherent with the graph having low energy (regarding a particular en-
ergy function), it is evaluated. Finally, all the subpathways are tested
one-by-one using a systematic approach to discover a non-homogeneous
subgraph which results in a list of candidate subgraphs that represent
the diﬀerence between the two conditions being studied. On the other
hand, clipper converts the pathway network into an undirected cycle-
free graph and applies two tests to this graph; one tests the behavior of
the whole pathway using graphical Gaussian models for each condition,
and the other identiﬁes the relevant signal paths.
Linear path based. Most approaches based on this concept only describe the
process without providing a tool [36, 37], however two approaches which
provide a tool are highlighted in this section: the Topology Enrichment
Analysis frameworK (TEAK)[38] and Diﬀerential Expression Analysis
for Pathways (DEAP)[39]. DEAP is a python algorithm which examines
any independent subpathway and calculates its diﬀerential expression
by adding or subtracting all the downstream nodes with catalytic or in-
hibitory relationships. Then, DEAP calculates an absolute expression level
value to determine which subpathway has the maximum value It also uses
a self-contained approach which assesses the signiﬁcance of each pathway.
TEAK uses linear (from root to leaf) and nonlinear (represented by join-
ing adjacent and overlapping feed-forward loop) subpathways. This ap-
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proach calculates a score for each subpathway based on expression data
and pathway structure, using a Bayesian Information Criterium (BIC)
for context-speciﬁc data and Kullback-Leibler divergence for case/control
data.
A summary of pathway analysis classiﬁcation methods can be shown in
Table 1.6 and Figure 1.7
name availability reference
ORA tools
Onto-Express Web [40, 41]
GeneMapp Standalone [42]
GOminer Standalone, Web [43]
FatiGO Web [44]
GOstat Web [45]
FuncAssociate Web [46]
GOToolBox Web [47]
GeneMerge Standalone, Web [48]
GOEAST Web [49]
clueGO Standalone [50]
FuncSpec Web [51]
GARBAN Web [52]
GO:TermFinder Standalone [53]
WebGestalt Web [54]
WebGestalt2 Web [55]
agriGO Web [56]
GOFFA Standalone, Web [57]
WEGO Web [58]
IPA Web 5
BayGO R-package [59]
ChipInfo Web [60]
PathMAPA Standalone [61]
ArrayXPath Web [62]
FCS tools
GSEA Standalone [63]
GSEABase R-package [64]
sigPathway R-package [65]
Category R-package [66]
SAFE R-package [67]
GlobalTest R-package [68]
PCOT2 R-package [69]
SAM-GS Standalone [70]
Catmap Standalone [71]
T-proﬁler Web [72]
FunCluster Standalone [73]
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GeneTrail Web [74]
GAzer Web [75]
FatiSCAN Web [76]
PathwayMiner Web [77]
DAVID Web [78]
Pathway Processor Standalone [79]
PT-base tools
ScorePAGE No implementation available [80]
Pathway-Express Web [81, 82]
SPIA R-package [83, 84]
NetGSA No implementation available [85]
BPAS Standalone [86]
Paradigm Standalone [87]
Subpathway-based tools
SubpathwayMiner R-package [32]
DEgraph R-package [33]
Clipper R-package [34]
Graphite Web Web [35]
DEAP Python algorithm [39]
TEAK Standalone [38]
PATHiWAYS Web [88, 89]
Table 1.6: Classiﬁcation of pathway analysis methods[29]. Several older
methods are shown and a new group of subpathway methods (SP-based meth-
ods) are added. Pathway analysis methods are classiﬁed into four groups.
Over-Representation Analysis (ORA) and Functional Class Scoring (FCS) are
enrichment methods that do not take the structure of the network into account.
Pathway topology (PT)-based methods do take the pathway structure, but use
pathway information as a whole. Finally, SP-based methods take the internal
substructures of the network that could lead to diﬀerent functionalities into
account.
5Ingenuity R©Systems, www.ingenuity.com
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Figure 1.7: Summary of pathway analysis methods classiﬁcation[29].
This methods are divided in four groups or generations. The ﬁrst three groups
ORA, FCS and PT-based (over-representation analysis, functional class scor-
ing, and pathway topology respectively) are methods designed to asses the
signiﬁcance of the pathway, whereas the fourth one Subpathway-Based meth-
ods (SB-methods) appeared last year and aims to classify subpathways
2Chapter
Motivation, objectives and
contributions
"The most exciting phrase to hear in science, the one
that heralds new discoveries, is not 'Eureka!' but
'That's funny...'"
 Isaac Asimov
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2.1 Motivation
Cellular processes are often carried out via intricate systems of interacting genes
and proteins, which are usually represented as biological pathways networks
(Section 1.3). Biological pathways are annotated as the result of extensive
eﬀort by hundreds of researchers who manually contribute their experimental
knowledge about a speciﬁc biological process by graphically representing it.
Therefore, pathways are the best representation of biological experimentally
validated knowledge for speciﬁc processes.
The impact of a speciﬁc condition on a pathway is broadly studied by
several approaches which are divided into four diﬀerent groups or generations
(Section 1.5). Each generation was developed to overcome limitations of the
methods in the previous generations, however most recent methods, SP-based
approaches, still have some major limitations in terms of biological modeling
and interpretation of subpathways.
The ﬁrst group of SP-based methods, considers a pathway as a subgraph of
the pathway graph. This deﬁnition implies that diﬀerent stimulus (understood
as the node that receives the external signal, i.e. start-point) and diﬀerent ef-
fectors (understood as the node that provokes the cellular response, end-point)
can be included in the same subpathway meaning that the functional interpre-
tation of the results could be confusing. This limitation is overcome by the
deﬁnition used for the second group of SB-methods, where a subpathway is
deﬁned as a linear path between a receptor (stimulus) and an eﬀector. There-
fore, diﬀerent linear paths can be established between the same stimulus and
eﬀector because each of the linear paths represent a subpathway. Nevertheless,
in reality, cellular functionality associated with the eﬀector gene is a combina-
tion of the signals received through all of the linear paths between a stimulus
and an eﬀector. To overcome this limitation in the biological interpretation of
subpathways, a new deﬁnition that combine both these ideas is proposed in
this thesis. A subpathway is considered to be the set of linear paths going from
a stimulus to an eﬀector, where the combinatorial eﬀects of all the linear paths
between a stimulus and an eﬀector are taken into account (Section 3.1.3).
Most of SP-based methods model information contained in pathway databases
(speciﬁcally the KEGG database) without taking into account the biological
meaning of the elements represented. Some of them consider an undirected
graph, thus losing the directionality of the signal pass [32, 33]. Others fail
to correctly modeling the information in the KEGG database [33, 35]. To
overcome this limitation this thesis describes the process for modeling KEGG
information to provide mathematical models that better reﬂect the biology
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underlying the pathway models.
An important aim of Bioinformatics is to develop tools for analyzing of
biological data which are accessible for non-expert users. Most of the tools
provided by SP-based methods are implemented in the statistical programming
language R, which drastically limits its use by inexperienced users, with the
exception of Graphite Web[35] which implements clipper approach[34] and
that provide a web-tool, and TEAK[38] that provides a standalone tool. In
order to accomplish this aim, all the methods developed in this thesis were
implemented in a web-tool called PATHiWAYS[89] (Section 4.7).
2.2 Objectives
The main objective of this thesis is to develop a methodology to analyze mi-
croarray expression data in a systems biology context. More speciﬁcally, we
aimed to develop a method to dissect pathways in smaller substructures called
subpathways, whilst retaining complete biological meaning: this tool was ana-
lyzed and experiment with two diﬀerent conditions which allowed the functional
diﬀerential behavior of subpathways to be assessed in a control-case experiment.
This global objective can be broken down into smaller tasks:
• Create a database of models that describe the behavior of each probe
set in diﬀerent Aﬀymetrix platforms. This database will be use as back-
ground data in the approach developed.
• Provide proper biologically oriented deﬁnitions of pathway objects and
their relations to the KEGG database, thus obtaining models representing
the underlying biology. Use these deﬁnitions to create a database of
modeled pathways and subpathways that will be used as background
structures for the analysis of expression data.
• Develop a statistical method for analyzing the diﬀerential activation be-
havior between two given samples in an expression dataset. This task
includes the development of methodologies to estimate the probability of
activation of each gene in the network and of signal transmission along
the predeﬁned subpathways, as well as the application of statistical tests
to compare the diﬀerential behavior of each of them.
• Implement a tool which performs the methodology in order to bring it to
the research community.
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2. P.Sebastian-Leon, E. Vidal, P. Minguez, A. Conesa, S. Tarazona, A.
Amadoz, C. Armero, F. Salavert, A. Vidal-Puig, D. Montaner, and J.Dopazo,
"Understanding disease mechanisms with models of signaling pathway
activities", BMC systems biology, vol.8, no.1, p.121, 2014
3. R.D. Hernansaiz-Ballesteros, F. Salavert, P. Sebastián-León, A. Ale-
man, I. Medina, and J. Dopazo, "Assessing the impact of mutations found
in next generation sequencing data over human signalig pathways", Nu-
cleic acids research, p.gk349, 2015
4. F. Eduati, LM. Mangravite, T. Wang, H. Tang, JC. Bare, R. Huang,
T. Norman, M. Kellen, MP. Menden, J. Yang, X. Zhan, R. Zhong, G.
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RR. Tice, A. Simeonov, I. Rusyn, FA. Wright, Y. Xie, S. Alaimo, A.
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Y. Jiao, G. Klambauer, M. Kuhn, MB. Kursa, R. Kutum, N. Lazzarini,
I. Lee, MKK. Leung, WK. Lim, C. Liu, FL. López, A. Mammana, A.
Mayr, T. Michoel, M. Mongiovì, JD. Moore, R. Narasimhan, SO. Opiyo,
G. Pandey, AL. Peabody, J. Perner, A. Pulvirenti, K. Rawlik, S. Rein-
hardt, CG. Rie, D. Ruderfer, AJ. Sander, RS. Savage, E. Scornet, P.
Sebastian-Leon, R. Sharan, CJ. Simon-Gabriel, V. Stoven, J. Sun, AL.
Teixeira, A. Tenesa, JP. Vert, M. Vingron, T. Walter, S. Whalen, Z.
Wi±niewska, Y. Wu, H. Xu, S. Zhang, J. Zhao, WJ. Zheng, D. Ziwei, and
J. Saez-Rodriguez, "Prediction of human population responses to toxic
compounds by a collaborative competition", Nature biotechnology, 2015.
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"Using activation status of signaling pathways as mechanism-based biomark-
ers to predict drug sensitivity" Scientiﬁc Reports [In Press], 2015
2.3.2 Conferences
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ages", Teacher, 3.5h.
March 2015 September 2014, March 2014 The Genomic of Gene Expres-
sion RNA-Seq Course, "Introduction to Linux and command line", Teacher,
3.5h.
March 2011 VIII International Course of Massive Data Analysis, "Introduc-
tion to R and NGS Bioconductor packages", Teacher, 1.5h.
March 2011 VIII International Course of Massive Data Analysis, "Statistical
Methods", Teacher, 3h.
June 2010 VII International Course of Massive Data Analysis, "Understand-
ing genome-scale experiments at the light of protein-protein interactions",
Assistant, 1h.
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Methods
"For every complex problem there's an answer that is
clear, simple, and wrong"
 H.L. Mencken
In this chapter the methods developed and used in this thesis are explained.
First, methods to generate background data are explained: pathway models
(Section 3.1) and probe set expression models (Section 3.2). These steps are
explained in the following sections and also appear in the method workﬂow
(Figure 3.1). Starting from an expression dataset, the probability of activa-
tion of any probe set belonging to this dataset is calculated (Section 3.3) using
the previously calculated mixtures of distribution(Section 3.2), summarized as
the probability of activation of nodes or complexes (See section 3.4) which is
propagated along the subpathways to estimate the probability of a subpathway
being activated (Section 3.5). Once the probabilities of all the subpathways are
compared, a statistical test is used to asses which ones are signiﬁcantly diﬀer-
ent between both conditions (Section 3.6). Finally, signiﬁcantly diﬀerentially
activated subpathways are represented in a graph in order to put pathway map
into a biological context (Section 3.7).
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Figure 3.1: Method's workﬂow Expression data coming from a two-condition
experiment is ﬁrst converted into probe set activation probability using pre-
calculated mixtures of probability distribution for each probe set on the plat-
form. These probabilities are then summarized into node and complex proba-
bilities using diﬀerent rules, and this ﬁgures are subsequently transmitted along
the subpathways using Inclusion-Exclusion principle to obtain the probability
of activation for each subpathway in the pathway. Finally, a statistical test
is applied in order to determined which subpathways changed to statistically
signiﬁcant degree between both conditions.
3.1 Pathway modeling
Information about the structure of the pathways was extracted from the KEGG
(Kyoto Encyclopedia of Genes and Genomes) database (See 1.4.2). This database
is considered the foremost reference knowledge base for the integration and
interpretation of large-scale molecular data sets, and is broadly used in path-
ways approaches. Information about nodes and their relationships is provided
in KGML (KEGG Markup Language) format. Although this format is exclu-
sive to KEGG, it is simple to parse because is very similar to the Extensible
Markup Language (XML) format1
Nevertheless, this database does have some disadvantages. The information
is computationally generated from manually deﬁned information about it. This
is hazy because the information about the ﬁgures provided by KEGG does not
1XML is a markup language that deﬁnes a set of rules for encoding documents. This
format is both human and machine-readable and is broadly used in databases storage.
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always match the information contained in the KGML ﬁle. Also, more than one
gene is provided in a node without clarifying what the correct interpretation
of this fact is (Section 3.4).
Metabolic and signaling pathways are diﬀerent in nature and thus have to
be modeled in a diﬀerent way. Metabolic pathways produce metabolites via the
action of enzymes (genes), while signaling pathways describe a signaling cas-
cade from stimulus to receptors that performs a function in the cell. This thesis
is focused on signaling pathways for two main reasons. First, signaling is closely
related with cancer processes and, secondly, because mathematically modeling
metabolic pathways, in the way proposed in this thesis2, is not straightforward
because many of reversible relationships exist that provoke cyclic behaviors.
Also, the whole metabolic pathway usually is a cycle where stimulus and re-
sponses are not clearly deﬁned.
3.1.1 KEGG Markup Language (KGML) structure
Information about nodes and relations in KEGG maps is provided in KGML
format (Figure 3.2). KGML ﬁles start with a header indicating which ver-
sion of KGML and KEGG the ﬁle belongs to. The ﬁrst element in the ﬁle is
called pathway and contains information about the pathway. Depending on
this pathway we can ﬁnd three elements: entry and, relation contain infor-
mation about nodes and edges respectively, and reaction contains information
about metabolic reactions and are out of the scope of this thesis.
KEGG entry
The entry element contains information about nodes in the pathway map
(Table 3.1). The name slot indicates which genes are contained in the node and
the type indicates which type the node is. Both are used to properly model the
network (Section 3.1.2) and estimate the probability of the node being active
(Section 3.4).
The type attribute has several values corresponding to diﬀerent types of
nodes (Table 3.2). Not all nodes deﬁned in the KEGG database participate
in signaling pathways. Speciﬁcally, only ortholog, gene, group, and compound
nodes are considered in signaling pathways. Enzyme and reaction are nodes
that act only in metabolic pathways, and map are nodes that represent other
2There exists several methods that model mathematically metabolic pathways, such Flux
Balance Analysis (FBA)[90], but are mostly based in optimization problems
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Figure 3.2: KEGG Markup Language (KGML) elements. Elements
included in signaling pathways are highlighted in purple: pathway, entry, and
relation. These elements contain general information about the pathway,
nodes, and edges respectively.
attribute explanation
id the ID of this entry in the pathway map
name the KEGGID of this entry
type the type of this entry
link the resource location of the information about this entry
reaction the KEGGID of corresponding reaction
graphics graphical information
Table 3.1: KEGG entry information. The information used in this thesis
is highlighted in bold.
pathways. These nodes are not considered because they lack of relations asso-
ciated with map nodes in KEGG database.
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type explanation
ortholog the node is a KO (ortholog group)
enzyme the node is an enzyme
reaction the node is a reaction
gene the node is a gene product (usually a protein)
group the node is a complex of gene products (usually a protein complex)
compound the node is a chemical compound (including a glycan)
map the node is a linked pathway map
Table 3.2: Node types in the KEGG database. Node types included in
signaling pathways are in bold
It is noteworthy that both the genes and ortholog nodes, can contain more
than one gene/ortholog inside. That is, a node does not always represent a
gene, but it can represent a set of genes. Interestingly, there are some analysis
approaches that model this situation as a set of genes that works indepen-
dently between them[33, 34]. However, this is not the most realistic assump-
tion. KEGG maps are static and their components are shared for diﬀerent
tissues and developmental stages. Most of the genes contained in a node be-
long to the same family, and share their functionality, but they are expressed
in diﬀerent tissues or in at diﬀerent developmental stages. For example, in the
VEFG signaling pathway (Figure 3.3a) we can ﬁnd a node, labeled as SPK
that includes two genes: sphingosine kinase 1 and 2 (SPHK1 and SPHK2).
According to UniProtKB/Swiss-Prot database[91] the function of both is to
catalyze the phosphorylation of sphingosine to form sphingosine 1-phosphate
(SPP)[92, 93], but they have a diﬀerent subcellular location. SPHK1 is located
in the cytoplasm[94] and nucleus, and SPHK2 has two isoforms, the ﬁrst lo-
cated in the cytoplasm and membrane (isoform 1) and the second in lysosome
membranes (isoform 2)[95, 93]. Therefore, we consider them as a simple node,
where the genes contained within it act alternatively to pass the signal along
the path.
Group nodes represent a diﬀerent situation. This label indicates that more
than one node acts cooperatively. That is, all nodes must be activated to
mantain its integrity. These nodes are considered to be complex nodes and their
behavior is modeled in a diﬀerent way than simple nodes. Other Subpathway-
based methods consider them as separate nodes, but this is not ideal because
nodes must act together to pass on signals, as is shown in Figure 3.3b. In
the PPAR signaling pathway, surrounding nodes are indicated as groups in the
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KGML; these groups are described as complexes in GeneCards[96] (one of the
most curated databases for gene information) and indicates that PPARs form
heterodimers with retinoid X receptors (RXRs) and that these heterodimers
regulate transcription of various genes3.
In KEGG maps, rectangles represent gene products, which are usually pro-
teins, but can also be RNA or other complexes; circles are other types of
molecules, usually chemical compounds, while round rectangles represent links
to other pathways. This information is contained in the graphics element
(Table 3.1) as well as in the position of each node and is used to deﬁne the
layout of the graphical output of the pathway (Section 3.7).
attribute explanation
name the label of this graphics object
x the X axis position of this graphics object
y the Y axis position of this graphics object
coords the polyline coordinates
type the shape of this graphics object
width the width of this graphics object
height the height of this graphics object
fgcolor the foreground color used by this graphics object
bgcolor the background color used by this graphics object
Table 3.3: KEGG graphics information. Information used for the develop-
ment of this thesis is highlighted in bold
3http://www.ncbi.nlm.nih.gov/gene?db=gene&cmd=Retrieve&dopt=full_report&list_
uids=5468
3.1. PATHWAYS MODELING 37
  
(a) VEFG signaling pathway
  
 
(b) PPAR signaling pathway
Figure 3.3: Examples of simple and complex nodes. (a) A node labeled
as SPK, in VEFG signaling pathway, includes information about two genes.(b)
Surrounded nodes in PPAR signaling pathway nodes are indicated as groups
in the KGML ﬁle
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KEGG relation
The relation elements contain information about the relationships that are
established for the node in the pathway map (Table 3.5).
attribute explanation
entry1 the ﬁrst (from) entry that deﬁnes the relation
entry2 the second (to) entry that deﬁnes the relation
type the type of the relation
subtype the class of the relation
Table 3.4: Relation information in KEGG database.
The type attribute indicate the class of the elements that take part in the
relation (Table 3.5) and the name attribute in the subtype slot indicates the
class of relation which has been established between the nodes (Table 3.6).
There is not an single subtype for each relation. For example a relation can
be a phosphorylation event that provokes inhibition of the upstream protein,
thus the relation element has two subtypes: phosphorylation and inhibition.
value explanation
ECrel enzyme-enzyme relation, indicating two enzymes catalyzing suc-
cessive reaction steps
PPrel protein-protein interaction, such as binding and modiﬁcation
GErel gene expression interaction, indicating a relation between a tran-
scription factor and target gene product
PCrel protein-compound interaction
maplink link to another map
Table 3.5: Relation types in KEGG database. Relation types included in
signaling pathways are highlighted in bold
Not all relationships deﬁned by KEGG are included in signaling path-
ways. Relationships between nodes can be deﬁned in terms of the activa-
tion/deactivation eﬀect on the upstream protein, i.e. its capacity to transmit
the signal along the path:
compound A compound binds another element to activate the upstream pro-
tein.
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value explanation
compound shared between two successive reactions (ECrel)
or intermediate of two interacting proteins (PPrel)
hidden compound shared between two successive reactions but not
displayed in the pathway map
activation positive eﬀects which may be associated with
molecular information
inhibition negative eﬀects which may be associated with
molecular information
expression interaction via DNA binding
binding/association proteins association
dissociation proteins disassociation
phosphorylation
molecular events
dephosphorylation
glycosylation
ubiquitination
methylation
Table 3.6: Relation names in the KEGG database. Relation names
included in signaling pathways are highlighted in bold
activation A downstream protein activates upstream protein.
inhibition Activation of the upstream protein is blocked.
expression Expression of the upstream protein is activated.
binding/association Both proteins bind to each other to regulate another
protein.
dissociation The separation of two bound proteins resulting of the activation
of the upstream protein.
phosphorylation The upstream protein is activated/inhibited by the addi-
tion of a phosphate group.
dephosphorylation The upstream protein is activated/inhibited by the loss
of a phosphate group.
ubiquitination The upstream protein is degraded by the action of a ubiquitin
protein.
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In KEGG pathway maps, the edges between rectangles represent functional
interactions and they can be directed, directed with a +p (phosphorylation),
directed with a −p (dephosphorylation, or directed with a bar at the end (in-
hibition).
3.1.2 KEGG signaling pathways modeling
First, KGML ﬁles were downloaded from the KEGG database (Release 66.0,
April 1, 2013). Information about the components of the network and their
relationships were extracted from KGML ﬁles using a PERL script.
The relations, except binding/association relationships, were simpliﬁed into
two possible events: activation and inhibition. Relations that provoke the
activation of the upstream protein, allowing the signal to pass through the
subpathway are considered to be activations. KEGG allows more than one
relation between nodes (Section 3.1.1), that is, a relation between two nodes
can be indicated as phosphorylation and inhibition together, and in this case
is a phosphorylation that produces an inhibition of the upstream protein. In
general, all relations are considered to be activations unless it is indicated as an
inhibition or ubiquitination in the KGML ﬁle. Ubiquitination is a relationship
where a ubiquitin protein is attached to another protein to provoke its degra-
dation which consequently causes an interruption of the signal passing through
the subpathway. Therefore, inhibition and ubiquitination are both considered
to be inhibitions, and other types or relations are considered to be activations.
The binding/association relation is diﬀerent to the others because it does
not indicate any modiﬁcation in the activation of adjacent proteins, but it does
indicate that two proteins must bind together in order for the signal to pass
along the path. This situation is similar to group nodes (Section 3.1.1), and
so it is modeled in the same way. Nevertheless, binding/association modeling
is not as evident as it is for group nodes, and consequently several proteins
which are related by binding/association are joined together with other nodes
in the network for other relations. Therefore, we had to establish some rules
to specify how these complex nodes bind (Figure 3.4):
• Nodes connected only by a binding/association relation are considered to
be complex nodes (Figure 3.4a).
• Nodes connected by both, binding/association and another relation (ac-
tivation or inhibition), are joined into a complex node (Figure 3.4b).
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• Nodes connected by a binding/association with nodes that provoke a
bifurcation are duplicated and are considered once in each bifurcation
subpathway (Figure 3.4c).
A B C D
A BC D
(a) Rule 1
A B C D
E
A BCE D
(b) Rule 2
A B
C
D
E
F
A
BC
BD
E
F
(c) Rule 3
Figure 3.4: Rules for complex nodes set. Two types of relationships are
considered in this ﬁgure: Activation/Inhibition (→), and binding/association
()
Modeling a binding/association relation in this way is one of the strengths
of this approach. Most SP-based methods consider this relationship as a non-
directed edge and consider the nodes that are related by it as independent, but
this modeling does not reﬂect the biology underlying these relationships. In
Figure (3.5) the WNT signaling pathway is modeled using the rules explained
in this section. Two types of nodes are considered: simple nodes (white) and
complex nodes (gray). The, relations are simpliﬁed into two types: activation
(black) and inhibition (red). Nodes in the shaded rectangle are joined by
binding/association relationships according to the KGML ﬁle and are indicated
as scaﬀold proteins in the KEGG map (Figure 3.5a). Once the modeling rules
are applied, some complex nodes are created (Figure 3.5b). It is of note that
not all the shaded nodes are joined together, in fact DVL1 node is duplicated
allowing the signal to pass through two subpathways.
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(a) KEGG map
(b) Modeled network
Figure 3.5: An example of WNT signaling pathway modeling. (a) The
KEGG map for the WNT signaling pathway (b) The modeled network for
the WNT signaling pathway. Only two types of nodes (simple/complex) and
relations (activation/inhibition) are considered.
3.1.3 Subpathway extraction
Once a pathway is modeled as indicated in section 3.1.2, it can be represented
by a graph where genes are nodes and their interactions are edges, although to
deﬁne a subpathway, some concepts about graph theory must be deﬁned[97]:
Graph A graphG = (V,E) in two sets V = {v1, ..., vN} and E = {e1, ..., eM} =
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{(vi, vj/(vi, vj) ∈ V xV )} where:
• The elements of V are called vertices (or nodes).
• The elements of E are called edges.
• Each edge has a set of one or two vertices associated with it, which
are called its endpoints. An edge is said to join its endpoints.
Adjacency A vertex vi is adjacent to vertex vj if they are joined by an edge.
Directionality A directed edge (or arc) is an edge ek = (vi, vj), in which one
of its endpoints is designated as the tail, and the other as the head (a
directed edge is directed from its tail to its head). A digraph (or directed
graph) is a graph where each of the edges is directed.
Degree The degree (or valence) of a vertex v in a graph G is the number of
proper edges incident to v.The in-degree of a vertex v in a digraph is
the number of arcs directed to v; and the out-degree of a vertex v is the
number of arcs directed from v.
Based on these concepts, we deﬁne an entry node (stimulus) as a node
showing zero in-degree, except if it acts as an inhibitor. Similarly, an exit
node (response) is a zero out-degree node. A set of adjacent nodes between two
nodes is considered to be a path. Finally, a stimulus-response subpathway is
deﬁned as the set of paths between an entry and an exit node. These stimulus-
response subpathways represent the way in which the signal is transmitted
along the pathway network. This transmission may occur along a single path
or via multiple paths between entry and response nodes (Figure 3.6). Each
subpathway, as deﬁned above, is an atomic functionality within the pathway.
To extract all the subpathways from a pathway, we developed an algorithm
in R that calculates all possible paths between an entry and an exit node. This
algorithm automatically discards looped paths and groups all the paths which
share the same entry and exit node in a subpathway.
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Figure 3.6: Subpathway elements Two diﬀerent entries and two diﬀerent
exits can be observed on this sample network, as well as two subpathways
deﬁned between them. The ﬁrst subpathway comprises two paths (two possible
routes that the signal can take from entry to exit).
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3.2 Probeset expression distribution modeling
A comparable measurement criteria is needed to assess the capacity of each
node to transmit a signal through a subpathway, however, the level of expres-
sion is not comparable itself (Section 1.2.2). In 2007, Efroni[7] proposed a
method to estimate the probability of a node's activity by modeling the ex-
pression level of a gene as a mixture of two distributions: one associated with
the active state of the gene and the other its inactive state. These mixtures
will serve as a template of the probability of activation of each probe set given
its expression value.
Consequently, we decided to use the activation probability for each probe set
as our measurement of the probe set's activity. Conceptually it is understood
that the classiﬁcation of genes into alternative states is a simpliﬁcation of much
more complex complexity patterns of gene behavior and action[18]. Therefore,
the expression of each probe set was modeled as follows:
p(x) = pi1p1 + pi2p2
where pi are the distributions of the active and inactive states and pii are the
estimated mixture coeﬃcients.
3.2.1 Data preprocessing
Each Aﬀymetrix DNAmicroarray measures a diﬀerent set of probe sets, and the
range of expression common to each probe set is also very diﬀerent. Therefore
the model of each probe set is dependent on the platform used to measure it.
Six expression microarray platforms were considered in this thesis, three human
(Homo Sapiens), two mouse (Mus Musculus) and one rat (Rattus norvegicus).
The modeled platform and its abbreviations are shown in Table 3.7.
In order to estimate the distribution of each probe set in each platform,
data from the Gene Expression Omnibus (GEO)[25] database was downloaded.
The GEOmetadb R-package from Bioconductor[98] was used to render a total
of 43,913 arrays for the selected platforms. These arrays were hybridized for
every type of human, mouse, and rat samples. Data collection covered an ample
spectrum of biological conditions including diﬀerent tissues, diseases, male and
female individuals, as well as diﬀerent cell lines.
For each set of arrays (one for each platform), raw data (.CEL ﬁles) were
downloaded, normalized in batches of 100 (because of memory size limitations)
using the RMA function from aﬀy [99] Bioconductor R-package and ﬁnally all
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Platform Abbreviation
Aﬀymetrix Human Genome U133 Plus 2.0 Array HGU133Plus2
Aﬀymetrix Human Genome U133A Array HGU133A
Aﬀymetrix Mouse Gene 1.0 ST Array Mouse1st
Aﬀymetrix Mouse Genome 430 2.0 Array MG430_2
Aﬀymetrix Human Genome U133A 2.0 Array HGU133A_2
Aﬀymetrix Rat Genome 230 2.0 Array RG230_2
Table 3.7: Selected platforms and their abbreviations. Three platforms
for Homo Sapiens (HGU133Plus2, HGU133A and HGU133A_2), two for Mus
Musculus (Mouse1st and MG430_2) and one for Rattus norvegicus (RG230_2)
are used
the batches were rescaled together using the quantile method in the limma[100]
Bioconductor R-package.
3.2.2 Estimation of mixture parameters
Mixtures modeling was performed using mixdist [101] CRAN (Comprehensive
R Archive Network) R-package, more speciﬁcally, the MIX function developed
by MacDonald in 1988[102]which analyzes histograms as mixtures of statisti-
cal distributions. This function is used to ﬁnd a set of overlapping component
distributions that gives the best ﬁt to the histogram using the maximum like-
lihood. MIX assumes that:
• Components can be described by either normal, log-normal, or gamma
probability distributions
• Data are grouped, in the form of numbers of observations over successive
intervals
The MIX method also performs a goodness-of-ﬁt test depending on the
chi-square approximation to the likelihood ratio statistic[103]. The degrees of
freedom are computed as the number of grouping intervals minus 1 minus the
number of parameters estimated.
The MIX function returns an estimated value for each of the parameters:
the mean and the variance of each distribution, mixture coeﬃcients and the
goodness-of-ﬁt p-value of the mixture. Mean and variance are not the exact
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the parameters, but are a linear combination of them. To estimate both the
parameters of the distributions and the mixture coeﬃcients, the following steps
were performed for each probe set:
1. Calculate the two highest picks in the expression distribution of the probe
set., which are used as the initial point in the calculation of the mixture.
2. Calculate the mixture that best ﬁts the distribution of the expression.
This step is done for gamma, normal and log-normal distributions.
3. Use the goodness-of-ﬁt p-value to choose the distribution that best ﬁts
the distribution between gamma, normal and log-normalization. The
distribution with the lowesst p-value is selected. This p-value can be not
signiﬁcant in both cases, because it is only used to compare the mixture
model that best ﬁts the expression distribution, although this distribution
does not ﬁt signiﬁcantly.
4. Estimate the parameters of the optimal distribution from the estimated
mean (µˆ) and variance (σˆ2). If the optimal distribution is normal, the pa-
rameters match, but if it is gamma or log-normal, the following parametriza-
tion was used:
Ga(kGA =
µˆ
θGA
, θGA =
σˆ2
µˆ
)
LN(µLN = 2log(µˆ)− σˆLN , σˆLN =
√
log(σˆ2 + 1))
5. An .RData object with the following information was used: the selected
distribution (best ﬁt) of the components of the mixture (p1 and p2), the
estimated mixture coeﬃcients for each distribution (pi1 and pi2) and their
estimated scale and shape parameters.
3.3 Probe set activation probability
Once a mixture distribution is estimated, the probability of a probe set being
in the active distribution can be estimated based on its expression value[7].
According to Bayes' Theorem, the activation probability of a probe set given
a speciﬁc expression value (x) is:
P (Active|x) = p(x|Active)P (Active)
p(x)
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where, according to Law of total probability,
p(x) = p(x|Inactive)P (Inactive) + p(x|Active)P (Active)
In terms of the mixture distribution, it can be written as:
P (Activo|x) = pi1p1(x)
pi0p0(x) + pi1p1(x)
where,
• pi0 = P (Inactive) y pi1 = P (Active) are the mixture coeﬃcients esti-
mated in the previous section.
• p0(x) = p(x|Inactive) y p1(x) = p(x|Active) are the mixture components
estimated in the previous section.
3.4 Node activation probability
There are two types of nodes in the modeled network: simple and complex
nodes (Section 3.1.1) that model diﬀerent biological situations. Simple nodes
can comprise more than one gene and indicate an OR relation between their
components, while complex nodes are composed of simple nodes joined by an
AND relation.
There are three types of simple nodes in KEGG signaling pathways: com-
pound, ortholog, and gene. Orthologs and compounds are not measured by
expression microarrays, therefore th probability of activation of both of them
is deﬁned in one single term4. Gene nodes can contain more than one gene
(Section 3.1.1) and any gene can be mapped by more than one probe set (Sec-
tion 1.2.1). Expression level is measured at the probe set level, so the set of
genes contained in a node is converted into a set of probe sets taking into
account that a probe set mapping more than one gene is removed from the
analysis where confused measures could be included, but is kept where all the
genes mapped by it are included in the same gene. The activation probability
of probe sets mapping to a node can be summarized using diﬀerent statistics:
the mean, median, maximum, minimum, and 90th, 95th and 99th percentiles.
All of these statistics should be valid, but according to the deﬁnition of sim-
ple nodes it is reasonable to use the most activated gene as a proxy for node
4These nodes are maintained in the KEGG structure for future implementations which
incorporate their measurements
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activation, because genes included in this type of node are signal transmission
alternatives. Therefore, in this thesis, the activation of a simple node is sum-
marized using the 90th percentile of the probe sets mapping to it; the maximum
was discarded in order to avoid extreme values.
On the other hand, complex nodes represent a set of nodes acting coopera-
tively (e.g. a scaﬀold protein), therefore, nodes comprising it are essential for
its integrity (signal transmission). Consequently, the activation probability of
a complex node is summarized by the minimum activation probability of the
simple nodes it includes.
3.5 Propagation of probabilities in the network
Once the activation probability of each node is estimated, must be propagated
along the subpathway in order to estimate its activation probability (Figure
3.7). This is done taking into account that:
• Two nodes joined by an activation (A → B) will transmit the signal if
both are active, so the probability of signal transmission is: P (A active)∗
P (B active)
• Two nodes joined by an inhibition (A a B) will transmit the signal
only if the inhibitor is not active, so signal transmission probability is:
P (A inactive) ∗ P (B active) = [1− P (A active)] ∗ P (B active)
• In subpathways formed by more than one signaling path, the signal can
be transmitted by each of them, so the inclusion-exclusion principle[104]
is used to estimate the signal transmission probability.
P (
n⋃
i=1
Ai) =
n∑
i=1
P (Ai)−
∑
i<j
P (Ai
⋂
Aj)+
=
∑
i<j<k
P (Ai
⋂
Aj
⋂
Ak) + · · ·+ (−1)n−1P (
n⋂
i=1
Ai)
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Figure 3.7: An example pathway with three possible inputs and three
possible outputs. Any of the output proteins triggers a diﬀerent pathway
functionality. The connection matrix shows how the input and output can
be connected through ﬁve diﬀerent subpathways. Any subpathway can be
traversed by diﬀerent paths. For example, the subpathway connecting pro-
tein A (ProtA) to protein H (ProtH) can be traversed by two diﬀerent paths,
represented by two node sequences (that, for the sake of the simplicity, are
equivalent to proteins in this sample): ProtA, ProtB, ProtD, ProtF, ProtH
or ProtA, ProtB, ProtD, ProtG, ProtH. On the right, the two interactions
between proteins are shown: the top right represents activation, with an ar-
rowhead line, and bottom right represents repression with a line with no arrow.
In the lower part there is an example to illustrate the way in which the proba-
bility of subpathway activation can be calculated from the combined activation
of the corresponding nodes. From top to bottom: i) probability of the signal
transmission through an activation action, ii) probability of the signal trans-
mission through a repression action, iii) an example of a simple bifurcating
sub-pathway, and iv) the probability of signal transmission along this pathway.
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3.6 Comparison in a control-case experiment
The probability of activation is not informative by itself, because biological
information is not easily extracted from a subpathway activation probability.
Subpathway activation probabilities are, by deﬁnition, small, considering that
they are the result of multiply several probabilities belonging to the [0,1] inter-
val. The larger the number of nodes belonging to a subpathway, the smaller
the activation probability. Therefore, these subpathway activation probabilities
are typically used for making comparisons. The biological meaning of having a
signiﬁcantly lower or higher activation probability value in a condition with re-
spect to another is clear because signiﬁcant changes in the signal transmission
probabilities in a functional subpathway are a cellular response to a change in
conditions.
Our main concern using this approach is to assess the diﬀerential activation
probability of every subpathway in each pathway, given the sample status (dis-
ease or control). This data for a given experiment is a matrix which columns
indicate samples for both groups to compare and rows indicate all the possible
subpathways in the selected pathways. Matrix values represent the activation
probability for each subpathway on each sample.
Two possible strategies can be applied to solve this problem: parametric
and non-parametric statistics. Parametric statistics assumes that data comes
from a known distribution, and inferences are made about the parameters of
the underlying distribution. On the other hand, non-parametric statistics do
not rely on data belonging to a particular distribution. The Student t-test and
multilevel modeling are used in parametric statistics, and Wilcoxon test is used
for non-parametric statistics.
3.6.1 Parametric testing
Two diﬀerent options were considered for parametric testing: the student t-test
and multilevel modeling.
The most well-known parametric test is Student t-test[105], and so it was
tested ﬁrst, although the subpathway probabilities are clearly not normally
distributed. This group of tests refers to any statistical hypothesis in which
the test statistic follows a Student's t distribution if the null hypothesis is sup-
ported, although it is most commonly applied when the test statistic follows
a normal distribution, given a known value of scaling term. A False Discov-
ery Rate (FDR) control[106] is then applied to correct the p-values obtained
for each subpathway in the pathway, which can be used to assess which sub-
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pathways show a signiﬁcant diﬀerence in activation between conditions. The
t-statistic estimation is used to assess which condition is more activated in each
signiﬁcant subpathway.
For multilevel modeling, an average activation probability for each pathway
was supposed, taking into account possible diﬀerences because of the status and
allowing inter-subpathway (intra-pathway) variation via a random subpathway
random eﬀect. This model uses a multilevel varying-intercept, varying-slope
regression with activation probability (pi) as an outcome, sample status (si)
as a predictor, and subpathway (j) as a group factor. The parameters associ-
ated with the status indicator variable(µβ for the whole pathway, βj for each
subpathay) have a simple and useful interpretation: they stand for the average
diﬀerence in activation probability between the disease and control samples.
This model can be viewed as an extension to the classical comparison of pro-
portions. In the standard approach, activation of each subpathway would be
compared independently of the rest of the sample and the variability corrected
for multiple comparisons. In the proposed model, subpathway and pathway
information are used together to estimate both the location and variability of
the parameters. Information is shared between all subpathways that make up
a pathway by shrinking each path estimator from the standard analysis value
(unpooled, considering the subpathways as independent) to the pathway over-
all average value (pooled, considering all paths together). The extent of the
shrinkage depends on the variability of each path: the more variable (less con-
sistent, less reliably informative) a path is, the more its estimation is moved
towards the overall average.
This allows multiple comparison problems to be avoided[107]. In this case,
we did not use a logit transformation on the activation probabilities, mainly
for the two following reasons:
1. The parameter interpretation is less intuitive (odds ratio vs. absolute
probability diﬀerences)
2. The instability of estimations in the presence of 'outliers' (extreme prob-
abilities) are a current hurdle in the development of more sophisticated
multilevel modeling techniques.
3.6.2 Non-parametric testing
Non-parametric testing was performed using the Wilcoxon test[108] imple-
mented in R (wilcox.test function) to compare the diﬀerence in the activation
probability of each individual subpathway in the pathway. A False Discovery
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Rate (FDR) control[106] was then applied in the same way as in the t-test
case. The p-value obtained was used to asses any subpathways with a signif-
icant diﬀerence in activation between conditions. Estimation of the location
parameter is used to asses which condition is more activated in each signiﬁcant
sub-pathway.
3.7 Graphical interpretation
Results can be shown in a table indicating each sub-pathway and their corre-
sponding p-values, FDR corrected p-value and a label 'UP/DOWN' indicating
if the activation probability is higher in the ﬁrst or in the second group re-
spectively. For a better understanding of these results in a pathway context,
signiﬁcant results are represented in a KEGG-like map. This representation
is obtained using the R-package igraph[109] in a ﬁrst approach[88, 89] and is
followed up by using CellMaps (http://cellmaps.babelomics.org/). Nodes
belonging to subpathways which are signiﬁcantly more activated in the ﬁrst
condition appear in blue, while those which were signiﬁcantly more activated
in the second condition appear in red. Nodes belonging to several subpathways
with diﬀerent behavior appear in purple (Figure 3.8).
Figure 3.8: Example of a graphical representation of the results5 in
the JAK-STAT signaling pathway . Nodes belonging to signiﬁcantly more
activated subpathways in the ﬁrst condition appear in blue, and ones which
weresigniﬁcantly more activated in the second condition appear in red. Nodes
belonging to several sub-pathways with diﬀerent behaviors appear in purple.

4Chapter
Data and results
"Look deep into nature, and then you will understand
everything better."
 Albert Einstein
This chapter starts with a summary of the data used to generate the back-
ground data: modeled pathways (Section 4.1) and probe sets' mixtures (Section
4.2). This is followed by an analysis to validate the methodology (Section 4.3).
I go on to describe some results obtaining by applying the developed approach
to real data (Section 4.4) in order to probe the utility of the methodology.
The method is them compared with other existing methods using a colorectal
cancer dataset (Section 4.5). PATHiWAYS approach was also used to take
part in the CAMDA'2013 challenge and the results are included here (Section
4.6). Finally, the repackaging of the approach into an user-friendly web-tool is
explained in section 4.7
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4.1 Selected pathways
Not all signaling pathways in the KEGG database could be modeled for three
main reasons:
• There were pathways which nearly formed a complete loop. As indicated
in section 3.1.3, looped paths are discarted, because these pathways can-
not be modeled.
• Pathways containing subpathways with a huge number of paths. In this
case, it is not possible to compute the Inclusion-Exclusion principle for-
mula within a reasonable period of time, and so these pathways are not
modeled.
• Nodes where the information available for diﬀerent species is inconsistent
or not suﬁcient to extract comprehensive subpathways.
According to these criteria, 27 human (Homo Sapiens) KEGG signaling
pathways were selected and modeled as previously described (section 3.1.3).
18 signaling pathways for mouse (Mus musculus) and 22 for rat (Rattus Nover-
gicus) were subsequenly included as they were undertaken for diﬀerent studies.
The selected pathways for each species are described in Table 4.1.
The number of subpathways in each pathway varied a lot (Figure 4.1), from
four subpathways in the Hedgehog signaling pathway to 179 subpathways in the
Cytokine-Cytokine receptor interaction pathway.
The distribution of the subpathway elements also diﬀereed depending on
the pathway (Figure 4.2). The number of nodes (a) can be very variable, as
is the case for the Apoptosis or Adipocytokine signaling pathway ; or it can be
constant as for example in the PPAR signaling pathway, where the subpath-
ways are composed of three nodes or Neuroactive ligand-receptor interaction,
Antigen processing and presentation, and Cytokine-Cytokine receptor interac-
tion pathways, whose subpathways comprise two nodes. Nodes can act as
activators or inhibitors: there are some pathways without inhibitors (e.g the
PPAR signaling pathway) and some with more inhibitors than activators per
subpathway (e.g. the WNT signaling pathway). Finally, there are pathways
composed of linear subpathways (e.g. the Tight junction) and others with a
large number of paths per pathway (e.g. the ERBB signaling pathway).
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Figure 4.1: Number of subpathways per pathway. There are pathways
with a large number of subpathways (e.g. the Cytokine-Cytokine receptor in-
teraction) as well as pathways composed by very few subpathways (e.g. the
Hedgehog signaling pathway)
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Environmental Information Processing
KEGG subgroup Pathway name Species
Signal Transduction
ErbB signaling pathway h,m,r
Wnt signaling pathway h,m,r
Notch Signaling pathway h,m,r
Jak-STAT signaling pathway h,m,r
Calcium Signaling pathway h,m,r
VEGF signaling pathway h,m,r
Hedgehog signaling pathway h,r
mTOR signaling pathway h
Signaling molecules
and interaction
Neuroactive ligand-receptor interaction h,m
Cell adhesion molecules (CAMs) h,m,r
Cytokine-cytokine receptor interaction h,r
ECM-receptor interaction h,r
Cellular process
KEGG subgroup Pathway name Species
Cell growth and
death
Apoptosis h,m,r
p53 signaling pathway h,r
Cell communication
Gap junction h,m,r
Tight junction h,r
Endocrine system
Insulin signaling pathway h,m
Adipocytokine signaling pathway h,m,r
PPAR signaling pathway h,m,r
GnRH signaling pathway h,m,r
Melanogenesis h,m,r
Immune system
Toll-like receptor signaling pathway h
B cell receptor signaling pathway h,m,r
T cell receptor signaling pathway h,r
Fc epsilon RI signaling pathway h,m,r
Antigen processing and presentation h,m,r
Chemokine signaling pathway h
Table 4.1: Selected pathways. Classiﬁcation of the selected pathways into
KEGG categories and according tothe species in which they are modeled.
h=human, m=mouse, r=rat
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Distributions of subpathways elements
Figure 4.2: Distribution of the diﬀerent numbers of elements compris-
ing a subpathway. (a) The number of nodes comprising the subpathway.
(b) The number of nodes acting as an activator in the subpathway. (c) The
number of nodes acting as an inhibitor in the subpathway. (d) The number of
paths in the subpathway
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4.2 The calculation of probe set mixtures
Table 4.2 contains information about the speciﬁc number of arrays for each
platform.
Platform Specie GEOid Total available arrays
HGU133Plus2 Homo Sapiens GPL570 3,034
HGU133A Homo Sapiens GPL96 5,293
Mouse1st Mus musculus GPL6246 683
MG430_2 Mus musculus GPL1261 19,558
HGU133A_2 Homo Sapiens GPL571 7,134
RG230_2 Rattus norvegicus GPL1355 8,211
Table 4.2: Available GEO arrays for each selected platform The number
of arrays avaliable in the Gene Expression Omnibus (GEO) database for each
of the selected platforms.
The number of modeled platforms and the distribution selected to model
each platform is represented in ﬁgure 4.3. Mixtures of gamma distributions gave
better ﬁts most for the probe sets in all platforms, and log-normal distributions
were never selected for the mixtures (and this option will also be discarted for
future analyses). The number of probe sets modeled for each platform was
variable depending on how represented pathway's genes were in the platform.
As an example of the algorithm used to ﬁt the mixture of distributions that
best represents the behavior of the probe set, let us consider the probe set
(201655_s_at). The density function for this probe set is represented in ﬁgure
4.4. Two diﬀerent distributions can be observed in the density of this probe
set, which are associated with an inactive and an active state respectively.
Once the developed algorithm is applied, two diﬀerent ﬁttings are consid-
ered, one associated with gamma distributions and the other associated with
normal distributions. A good-of-ﬁtness p-value associated with each of these
ﬁttings was also considered in order to choose the best ﬁtted mixture of distri-
butions. In the case of 201655_s_at probe set, the ﬁtted mixtures are: (Figure
4.5)
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Seleted distributions for each platform
Figure 4.3: The number of selected distributions for each platform.
The number of mixtures of gamma distributions is represented in red and
number of mixtures of normal distributions is shown in green. There were
no mixtures of log-normal distributions selected for any platform. The num-
ber over each bar represents the total number of probe sets modeled for each
platform.
F (x) = 0.393×Ga(x|k = 59.401, θ = 0.113) +
+0.607×Ga(x|k = 132.299, θ = 0.067)
F (x) = 0.327×N(x|µ = 6.495, σ = 0.736) +
+0.673×N(x|µ = 8.793, σ = 0.843)
In this case the normal distribution is selected since its good-of-ﬁtness p-
value is lower (p=0.16). Therefore, for future calculations of the probability
of this probeset being active, the mixture of normal distributions with the
estimated parameters will be used.
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Figure 4.4: Density function of the expression level of the 201655_s_at
probe set
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Figure 4.5: Mixtures associated with the 201655_s_at probe set. (a):
Gamma distributions (b): Normal distributions
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4.3 Performance of the methodology
To test the proportion of false positives produced by any of the methods con-
sidered (multilevel modeling, t-test and Wilcoxon-test) we ﬁrst created a large
dataset containing samples in the same condition. It is important that the
methodology developed must not ﬁnd any signiﬁcant subpathway in any of
the combinations of samples chosen, therefore subpathways which were found
to be signiﬁcantly diﬀerent between the same conditions were considered to
be false positives. We use a large pediatric acute myeloid leukemia (AML)
[110, 111] dataset which contains expression microarray data for 237 bone
marrow and peripheral blood samples, hybridized to Aﬀymetrix U133 Plus
2.0 arrays. This dataset was downloaded from the GEO database (identiﬁer
number GSE17855 ). N and M samples representing the control and disease
samples respectively, were selected randomly from the AML dataset, and we
performed, 500 simulations for each combination of sample sizes (see Table 4.3
and Figure 4.6).
N M
5 5
5 20
10 10
10 100
50 50
50 100
100 100
Table 4.3: Sample sizes considered for the acute myeloid leukemia (AML)
dataset simulations
As shown in Figure 4.6, multilevel testing gave rise to a huge proportion of
false positives (signiﬁcant subpathways) in all the cases considered, and there-
fore shows a low speciﬁcity and was not suitable for ﬁnding any real changes in
the data. However, both the Wilcoxon and student-t tests behave similarly and
had a level of false positives (type-I error) of less than 0.05, and consequently
these two test have high speciﬁcity.
The proportion of false positives was also tested using simulated data.
Speciﬁcally, we simulated uniform random values between zero and one repre-
senting the probabilities of the probe sets. Following this, normally distributed
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Figure 4.6: Simulation results using the acute myeloid leukemia
(AML) dataset for the three diﬀerent methods considered: multilevel mod-
eling, the t-test and the Wilcoxon test
noise was added to the probability for each probe set probability. Diﬀerent
levels of noise are considered by using a normal distribution centered on zero
and with diﬀerent standard deviations (σ = 0.25, 0.1, 0.05, 0.025, 0.01). There
were no big diﬀerences between diﬀerent sample sizes, as shown in Figure 4.6,
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and so the same sample size was used in these simulations. the proportion of
false positives obtained with each method is shown in ﬁgure 4.7.
Figure 4.7: Simulation results using simulated dataset for the three con-
sidered methods: multilevel modeling, t-test and Wilcoxon test
Additionally, two other microarray datasets were used to check the pre-
dictive performance of the subpathway probabilities estimated using the ap-
proach we developed. This predictive performance can be considered represen-
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tative of a low number of failures to detect real activations (false negatives)[7,
112]. We analyzed a breast cancer[113] study as well as and another dataset
with increased expression in AML[114] (downloaded from the GEO database
with identiﬁers GSE27562 and GSE9476 respectively), using PATHiPRED
webtool1[115]. Support Vector Machine (SVM)[116] was used to classify the
samples and the accuracy of the classiﬁcation was evaluated using ten-fold
cross validation[117] taking the following parameters into account: proportion
of correct classiﬁcation (PCC) and area under the curve (AUC). The results
obtained for both datasets are shown in table 4.4. Importantly, the accuracy of
the predictors based on subpathway probabilities is close to one, thus showing
that they have a high prediction power and consequently high sensitivity.
Dataset PCC AUC
Breast cancer 0.99 0.99
AML 0.96 0.95
Table 4.4: Prediction results for the breast cancer and AML dataset.
Two parameters were considered to evaluate the accuracy of the prediction: the
proportion of correct classiﬁcation (PCC) and the area under the curve (AUC)
4.4 Results using real data
4.4.1 Colorectal cancer experiment
The method developed in this thesis was tested using a colorectal cancer (CRC)
dataset [118] (GEO database identiﬁer GSE4107 ) by comparing it with other
methods (section 4.5). Some of the relevant results are highlighted in this
section and a complete set of results from this experiment are included in
Appendix B, although only some relevant results that probe the value of the
proposed method are highlighted in this section.
CRC dataset was initially used to extract a relevant gene subset to early on-
set colorectal cancer. The sample contains 22 RNA samples extracted from the
colonic mucosa of healthy controls (10 samples) and patients(12 samples)who
were aged 50 or less and were Chinese. The RNA was analyzed using the
Aﬀymetrix Human Genome U133 Plus 2.0 Array.
1See 5.1 for a complete explanation of this tool
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Several pathways are known to be evolved in the development of colorectal
cancer, and we will speciﬁcally focus on three of these in this section: VEGF
signaling pathway, JAK-STAT signaling pathway and WNT signaling pathway.
It is known that, human colorectal tumors produce vascular endothelial
growth factor (VEGF) whose expression is up-regulated in tumor cells by both
cyclooxygenase-2 (COX-2) and PGE2 and is directly correlated to neoangio-
genesis and clinical outcome[119]. The COX-2 gene is included in node the
named PTGS2. In addition, the increase of the activity of COX-2 is connected
with PGI2 production in colorectal carcinomas[120]. According to our results
subpathway that ends in this node is signiﬁcantly more activated in colorectal
cancer patients (See ﬁgure B.13). VEGF-A also increases the vascular perme-
ability to plasma and plasma proteins, that is a characteristic property of tumor
microvasculature, a critical early step in tumor stroma generation[121]. In line
with this, as shown in Figure B.13, a subpathway whose endingpoint function
is permeability is signiﬁcantly more activated in colorectal cancer patients.
VEGF SIGNALING PATHWAY
Figure 4.8: Results from the VEGF signaling pathway in the colorectal
cancer study
The JAK-STAT signaling pathway is also aﬀected in colorectal cancer, its
inhibition reduces tumor cell invasion in colorectal cancer cells[122, 123]. Sig-
niﬁcant subpathways identiﬁed using the methodology developed in this thesis
include functions which are closely related with cancer development such as
growth, proliferation, fate determination, development, immunity, cell cycle
and antiapoptosis (Figure 4.9).
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JAK-STAT SIGNALING PATHWAY
Figure 4.9: results from the JAK-STAT signaling pathway in the colorectal
cancer study
Finally, the WNT signaling pathway (Figure4.10) is frequently aﬀected
in colorectal cancer. This pathway comprises by three diﬀerent pathways:
canonical (Wnt/β-catenin cascade), and non-canonical (Wnt/Planar cell po-
larity(PCP), and Wnt/Ca2+ mediated). The results obtained after applying
our method revealed signiﬁcantly increased non-canonical pathways activity.
Genes belonging to the Wnt/PCP pathway, such as RhOA, RAC and JNK are
known to be upregulated in CRC cancer [124], which explains the increase in
the activity of the subpathway leading to JNK2.
2labeled as MAPK8 in the pathway representation
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WNT SIGNALING PATHWAY
Figure 4.10: Results from the WNT signaling pathway in the colorectal
cancer study
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4.4.2 Models of obesity
In a previous study adipose tissue macrophages (ATMs) obtained at 5 ans 16
weeks of age from wild type (WT) and ob/ob mice were characterized[125].
ob/ob is a mutant mouse model that eats excessively and becomes obese and
is commonly used in type II diabetes studies. We used this data to study this
ATM characterization from a subpathway-based point of view, and obtained
compatible results. The dataset used for this analysis was downloaded from the
GEO database under identiﬁer GSE36669. This dataset included 15 samples
describing 2 genotypes (WT and ob/ob) at 2 time points (5 and 16 weeks) (as
shown in Table 4.5). The RNA samples were analyzed using Aﬀymetrix Mouse
Gene 1.0 ST Array microarray.
genotype time point #samples
WT
5 weeks 4
16 weeks 4
ob/ob
5 weeks 3
16 weeks 4
Table 4.5: Experimental design of ATM dataset. 15 samples describing
2 genotypes (WT and ob/ob) and 2 time points (5 and 16 weeks).
A predominant M2 anti-inﬂammatory phenotype was observed in 16-weeks-
old WT ATMs as well as 5-weeks-old ob/ob ATMs. Conversely, 16 weeks old
ob/ob ATMs had switched to a predominantly M1 proinﬂammatory phenotype,
which is associated with severe insulin resistance, diabetes, and proinﬂamma-
tory macrophages in adipose tissue. In contrast, after 16 weeks, the WT ATMs
could still control their carbohydrate metabolism and progressively expanded
their adipocyte tissue. This process is represented in the comparison between
5-weeks-old and 16-weeks-old wild type mice. Concretely,WNT signaling path-
way (Figure 4.11) signiﬁcantly activated the Wnt/β-catenin canonical which
triggered the cell cycle. The role of canonical pathway in tissue remodeling by
weight gain has already been identiﬁed [126, 127].
The VEGF signaling pathway also contributes to remodeling adipose tissue
during age-related growth expansion[128] (Figure 4.12). Its activity increases
as demand for adipose tissue expansion increases as well as in hypoxia which
produces an increase in the adipose tissue vascularization.
Finallly, subpathways in the Apoptosis pathway are also activated in 16-
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WNT SIGNALING PATHWAY
Wnt/Ṃ-catenin
Planar cell 
polarity (PCP)
Wnt/Ca2+
Figure 4.11: Results from WNT signaling pathway in the adipose tis-
sue macrophages (ATM) dataset. Wild type 5 weeks old were compared
with wild type 16 weeks old mice and we found a signiﬁcant activation of
subpathways which trigger cell cycle in the canonical Wnt/β-catenin pathway.
week-old ob/ob mice compared to the Wild type animals (Figure 4.13). Specif-
ically, caspase substrate cleavage is activated, as well as subpathways related
with survival, apoptosis and degradation. These results correlate with the
huge amount of fat depositio, inﬂammatory responses, and adipocyte crowns
of apoptotic adipocytes which are characteristic of the ob/ob mouse phenotype
as it ages.
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VEGF SIGNALING PATHWAY
Figure 4.12: Results from VEGF signaling pathway results in the adi-
pose tissue macrophages (ATM) dataset. Wild type 5 weeks old were
compared with wild type 16 weeks old mice and we found a signiﬁcant acti-
vation of subpathways ending on PGI2 production, Focal adhesion turnover,
actin reorganization, and permeability
APOPTOSIS
Figure 4.13: Results from Apoptosis in the the adipose tissue
macrophages (ATM) dataset. Wild type 16-weeks-old were compared with
ob/ob 16 week old mice and we found general activation of several subpatwhays
in Apoptosis pathway which trigger opposite functionalities as apoptosis or sur-
vival.
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4.4.3 Stem cells
This dataset was used in [129] to characterize changes in human hematopoi-
etic stem cells (HSCs) and progenitor cell populations during aging. It was
downloaded from GEO database under the identiﬁer GSE32719 and includes
27 HSC samples from healthy, hematologically normal (14 samples), young (5
samples), and elderly (8 samples) human bone marrow. The analysis carried
out in the original study suggested that there is a coordinate deregulation in
genes associated with cell cycle, hematological system development and func-
tion, cellular growth and proliferation, and humoral inmune response in elderly
HSC compared with younger ones[130]. This behavior was highlighted when
we analyzed the data using our method to show that a subpathway triggering
proliferation, diﬀerentiation, and Immune response is signiﬁcantly activated in
older HSCs compared with young HSCs (Figure 4.14). Therefore, the orig-
inal study discovered gene expression signatures and our developed method
uncovered the activation mechanisms used by the cell.
T-CELL RECEPTOR SIGNALING PATHWAY
Figure 4.14: Results from T-cell receptor signaling pathway in the hu-
man hematopoietic stem cells (HSC) dataset. Subpathway which trigger
Proliferation, Diﬀerentiation and Immune response is signiﬁcantly activated in
older HSC compared with young HSC.
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4.4.4 Fanconi Anemia - Cross-talk between pathways
Similarly to genes, signaling pathways do not act alone, but rather they are
connected among themselves to form a global pathway that controls cell sig-
naling processes. Therefore, results in one pathway can potentially reveal the
precise mechanisms which trigger a particular biological response in another
pathway, that is, the functional consequences in one pathway can provoke the
activation/inhibition of subpathways in another pathway3. Observing the com-
bined behavior of signaling pathways in a diseased cell can eventually reveal
interesting details about the overall mechanism of the disease and thus help in
the inference of ways to intervene.
To illustrate this concept, we analyzed a dataset from Fanconi Anemia (FA),
a disease in which signaling plays an important role. This dataset was used
in [131] to identify transcriptional diﬀerences between bone marrow cells from
11 normal volunteers and from 21 children and adults with Fanconi anemia.
It was downloaded from the GEO database under the identiﬁer GSE16334.
FA is a rare chromosome instability syndrome that is characterized by aplastic
anemia as well as a susceptibility to cancer and leukemia [132]. Disruption
of apoptotic control is a hallmark of FA, ans it has been proposed that this
explains the phenotype of the disease to some extent[133] and one of the genes
related to the disease, FANCC, is thought to be involved in Jak-STAT signaling
and apoptotic signaling[132]. Modeling of both pathways using the data and
our method allows us to pinpoint the mechanisms by which Jak-STAT signaling
pathway speciﬁcally triggers one of the survival circuits in the apoptosis pathway
that eventually causes the disease (Figure 4.15).
Centering on the Jak-STAT results (Figure 4.15a), the subpathways leading
to Growth Proliferation (via the PIM1 and CISH genes) are inhibited in FA
patients and the subpathways leading to Antiapoptosis (via the AKT3 gene)
are activated. This antiapoptotic behavior is directly associated with the Apop-
tosis pathway (Figure 4.15b). Three functionalities appear to be signiﬁcantly
inactive in FA: Cleavage of caspase substrate, Degradation, and Apoptosis
(via the BAD, DFFA and CASP6 genes respectively); whereas Survival (via
BCL2L1, BIRC2 and BCL2 genes) is signiﬁcantly active. Therefore, the ﬁ-
nal consequence is that antiapoptotic pathway activity in FA is higher than
in normal cells, although, apoptosis does still occur[133], most likely through
the circuits that ending at the BAX and/or TP53 genes(Figure 4.15b), whose
activity is not signiﬁcantly diﬀerent between normal and FA patients. This
observation suggests that known the features of FA, such as hypersensitivity
3For example, the ﬁnal gene of one subpathway can be initial signal in another pathway
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JAK-STAT SIGNALING PATHWAY
(a) JAK-STAT signaling
APOPTOSIS
(b) Apoptosis
Figure 4.15: Models of the (a) JAK-STAT and (b) Apoptosis pathways
in FA along with the corresponding signiﬁcant changes in the signaling circuit
activities.
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to DNA cross-linking agents [134, 135] or chromosomal instability [135] may
be a consequence of the abnormal survival of cells with damaged DNA. In
fact, recent reports have conﬁrmed that FA proteins participate directly in
canonical signaling pathways that inﬂuence survival and hematopoietic cells
self-replication[131].
4.5 Comparison with other approaches
The deﬁnition of subpathways proposed in this thesis is not exactly the same
as any of the other pathway analysis approaches, and so it is not possible
to compare results in a straightforward way. However, in this section, the
results obtained from analyzing the CRC dataset (Section 4.4.1) were used to
compare the approach described here with other methods that are typically
used to analyze expression data in pathway context.
The simplest analysis that can be done in a pathway context is the graphical
comparison of the diﬀerential behavior of each individual gene in a pathway
context. We calculated diﬀerential expression changes using limma[100] R-
package and represented them in a pathway-context (Figure 4.16b) using the
following scale: red for up-regulated, blue for down-regulated and white for no
diﬀerential expression, where intensity of the color depended on the signiﬁcance
of the diﬀerential expression. The diﬀerential expression and PATHiWAYS
results for the VEGF signaling pathway are displayed in Figure 4.16. It is worth
noting that it is not possible to extract conclusions about subpathway activities
from the information obtained. It is common that diﬀerent gene up- and down-
regulations compensate each other so that no ﬁnal change is produced in any
of the subpathway activities (Figure 4.16a). Therefore, signiﬁcantly activated
or deactivated genes with no direct eﬀect in this pathway, may be acting in
another pathway where its diﬀerential activity is not compensated by the other
genes acting in the network.
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VEGF SIGNALING PATHWAY
(a) subpathway-centered
VEGF SIGNALING PATHWAY
(b) gene-centered
Figure 4.16: Methods comparison. Comparison of the results obtained ap-
plying: (a) subpathway-centered approach, PATHiWAYS results for the
VEGF signaling pathway and (b) gene-centered approach, representation
of the diﬀerential expression of each gene where red represents over-expression
and blue under-expression. The intensity of the color is related with the mag-
nitude of the diﬀerential expression
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As described in section 1.5, the methods developed for pathway analysis can
be divided into four generations. Methods included in ﬁrst three generations
provide an enrichment analysis of the pathway taken as a whole, without dis-
tinguishing between the diﬀerent subpathways that compose it,meaning that
our results are not directly comparable with the results obtained with these
methods. However, we used a method that corresponds with each of these gen-
erations to analyze the CRC dataset and the results obtained were compared
with the PATHiWAYS results as far as possible (Table 4.6).
To compare the PATHiWAYS results with ORA tests (ﬁrst generation
methods) we use the FatiGO[44] web-tool included in the Babelomics[136] plat-
form. The input for the tool is a list of genes ranked by the statistics obtained
from a diﬀerential expression experiment. The upper and lower part of this list
(corresponding with the most up- and down-regulated genes) can be compared
to each other or with the complete list of genes in the genome. This tool returns
a list which is enriched in the genes which map to each pathway. The results
obtained are included on Table 4.6 in the columns named: UP vs DOWN which
compares upregulated and downregulated genes; UP vs ALL which compares
upregulated genes with all the genes included on the microarray4; and DOWN
vs ALL which compares downregulated genes with all the genes included on
the microarray.
Results from a functional class scoring (FSC) test, representative of the
family of GSEA tests which does not require gene pre-selection were compared
with PATHiWAYS results. More speciﬁcally, the Fatiscan[137] web-tool in-
cluded in Babelomics platform was used to asses which pathways are enriched
in genes with decreased gene expression. The results obtained with this method
are included in table 4.6 in the GSEA column.
Finally, to compare the results from our method with those from third gen-
eration of pathway analysis methods, the Signaling Pathway Impact Analysis
(SPIA)[83] approach was selected. This method uses the information from a
list of diﬀerentially expressed genes and their log-fold changes together with
signaling pathways topology, in order to identify the pathways which are most
relevant to the condition being studied. The CRC data was analyzed using
SPIA R-Package[84] and results obtained are included in Table 4.6 under the
SPIA column.
First column in Table 4.6 contains the name of the pathway. The next
three columns, collectively labeled as circuits, list the number of sub-pathways
4We use a personal annotation to avoid noise which include only genes measured by the
microarray
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in the pathways (Total) and the number of them signiﬁcantly activated in
cases with respect to controls (Case) or vice versa (Control) in the compari-
son, respectively. The three next columns, collectively labeled as SEA, list the
results of a conventional functional enrichment test in three situations: UP vs
DOWN) when the signiﬁcantly upregulated genes are compared to the signiﬁ-
cantly downregulated genes, UP vs ALL) when signiﬁcantly upregulated genes
are compared to rest of genes, and DOWN vs ALL) when signiﬁcantly down-
regulated genes are compared to the rest of genes. UP, DOWN and ALL means
where the major part of the pathway lies in the comparison. Signiﬁcantly up-
and downregulated genes are obtained by a conventional t-test with multiple
test adjustment as implemented in the Babelomics program. Although the
trends of the results are coincident with the other analyses, none of them re-
sulted signiﬁcant. The column labeled GSEA contains a version of GSEA test
implemented in the Babelomics program. The * and the boldface indicate the
trend is signiﬁcant according to the test. The last column, labeled as SPIA,
contains the result of the application of the pathway impact analysis
From table 4.6 we can conclude that no discrepancies between the results
obtained using the SPIA (that take pathway structure into account) and the
PATHiWAYS method stood out. In some cases, SPIA's behavior is closer to
taht of GSEA, probably because that both methods return a global score for the
pathway. However, the method proposed in this thesis goes further to detect
speciﬁc aspects of pathway activity. For example the VEGF signaling pathway
is known to be active in cancer, and its inhibition has been suggested as an
anticancer therapy [138]. Several subpathways in this pathway were detected as
signiﬁcantly active by our approach but not by the alternatives5. Similary, the
Jak-STAT signaling pathway is implicated in CRC, and its disruption reduces
tumor cell invasion[122]. In this case, both GSEA and our method6 detected
this behavior, but SPIA did not. Therefore, the PATHiWAYS method detects
pathway activity detected by other methods, but also detects the activation of
speciﬁc signaling functionalities that other methods are unable to detect.
5Figure B.13
6Figure 4.9
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Finally, two subpathway-based methods were run with the CRC dataset
and compared with our results: DEGraph[33] and clipper[34], concretely their
web-tool called GraphiteWeb[35]. However, these methods also have a dif-
ferent deﬁnition of subpathway, making the results no directly comparable.
Concretely, both methods deﬁne a subpathway as a clique (Section 1.5).
Two examples of DEGraph results are shown in ﬁgures 4.17,4.18.
The Figure 4.17shows the signiﬁcant DEGraph and PATHiWAYS results.
DEGraph returns the whole pathway as a signiﬁcantly aﬀected module (Figure
4.17a), whereas with our method highlights diﬀerent behaviors in pathway de-
pending on the diﬀerent stimulus and responses (Figure 4.17b). As previously
mentioned in section 3.1, this example shows incorrect KEGG information
modeling, because DEGraph considers the PPAR and RXR proteins to be in-
dependent signal entries in the network, even though in reality they form a
complex and behave cooperatively.
In the case of the ErbB signaling pathway (Figure 4.18), two diﬀerent path-
ways are highlighted as signiﬁcant by the DEGraph results (Figures 4.18a,
4.18b). The ﬁrst subpathway represents the central part of the pathway and
was also located by the PATHiWAYS approach (concretely subpathways end-
ing in JUN and ELK1). The second subpathway identiﬁed as signiﬁcant by
DEGraph is in fact formed by two separate nodes which contain several genes.
DEGraph considers them to be independent, but according to KEGG infor-
mation ans as previously discussed in section 3.1, they are alternative signal
transduction pathways.
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(a) DEgraph results
(b) PATHiWAYS results
Figure 4.17: DEGraph and PATHiWAYS signiﬁcant results on PPAR
signaling pathway
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(a) First DEgraph signiﬁcant subpathway (b) Second DEgraph signiﬁcant subpathway
(c) PATHiWAYS results
Figure 4.18: DEGraph and PATHiWAYS signiﬁcant results from ErbB
signaling pathway
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The signiﬁcant results from GraphiteWeb are shown in Table B.197. A
large number of pathways, such as Cocaine addiction, African trypanosomiasis,
Long-term depression, Salivary secretion, and many others that are completely
unrelated to cancer are obviously false positives. Forexample, in the VEGF
signaling pathway (Figure 4.19), clipper only detects a portion of the sub-
pathway leading to the production of COX2 via PTGS2 (prostaglandin G/H
synthase and cyclooxygenase), which is known to be activated in CRC [139, 119]
and is detected by our approach.
Finally, it is important to highlight that in last months Li published a
new paper comparing subpathway-based methods where PATHiWAYS were
included[140]. He propose a new approach called sub-SPIA and compare it
with some of the existing methodologies: SPIA, clipper, DEGraph and PATHi-
WAYS, and he concludes that pathways identiﬁed by sub-SPIA and PATHi-
WAYS generally play important roles in the entire system and reﬂect the hub
characteristic of the identiﬁed pathways. But, again, subpathway deﬁnition
lacks of biological interpretation on this approach.
7A complete version of the results as well as representa-
tions can be consuted in http://graphiteweb.bio.unipd.it/results/
f03dfb1161af34816216f5d4e043d9ccc4c66cfbfca60cdd8c490060b12266b1/
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(a) GraphiteWeb results
(b) PATHiWAYS results
Figure 4.19: VEGF signaling pathway signiﬁcant results from
GraphiteWeb and PATHiWAYS approaches
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4.6 Drugs behavior - CAMDA challenge
CAMDA (Critical Assessment of Massive Data Analysis) is a well-recognized
annual conference recently called the 'Olympics of Genomics'. This is a contest
to introduce and evaluate new approaches and solutions to the 'Big Data'
problem8. Therefore, CAMDA is a data analysis challenge which focuses on
the analysis of big heterogeneous data sets. These data sets are provided by
the organizers along with some questions about the data which the applicants
must answer. Research groups in the ﬁeld of bioinformatics, data analysis, and
statistics propose new techniques for handling and processing these data sets,
the combination of multiple data sources, and computational inference, and
best applications are invited to present and discuss their methods during the
conference.
We use the approach developed in this thesis to analyze the data provided
for 12th annual conference (CAMDA 2013). The data provided in one of the
challenges of this contest was the TGP dataset from the Japanese Toxicoge-
nomics Project[141] that contains over > 21, 000 arrays for rats treated with
mainly human drugs and proﬁled using the Aﬀymetrix RAE230_2.0 GeneChip.
In this case, only the data for liver tissue (both in vivo and in vitro) is provided.
The challenge questions for these data were:
Question 1 Can we replace the animal study with in vitro assay?
Question 2 Can we predict the liver injury in humans using toxicogenomics
data from animals?
We tested ﬁrst question using the PATHiWAYS[89, 88] approach. First,
more than 10,000 samples from the Aﬀymetrix RAE230_2.0 GeneChip were
downloaded from the GEO[25] database in order to estimate the mixtures for
each of the probe sets measured (as explained in Section 3.2). Rat pathways
information was also downloaded from the KEGG[27] database and modeled
as indicated in section 3.1.
We then carried out independent comparisons between all of the doses of
each drug tried in vitro and in vivo, and studied which circuits in which path-
ways displayed a signiﬁcant change in activity when the drug was induced, as
well as the type of change (activation or inhibition).
A total of 931 diﬀerent circuits from all the pathways were aﬀected by one
or more drugs. Cell lines were aﬀected more by drugs than the corresponding
8Referring to the explosion of new techniques that generate biological datasets (See Sec-
tion 1.3)
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in vivo counterparts (by an average of more than 25% ) as shown in Figure
4.20,the mean number of drug aﬀected subpathways in vitro are represented in
blue, in vivo in red, and the intersection between them n orange. This indicates
that, despite the disparity in global gene expression, the global behaviors are,
probably, not as radical as was indicated by Lukk[142].
Figure 4.20: Mean number of drug aﬀected subpathways per pathway,
where the mean number of drug aﬀected subpathways in vitro are represented
in blue, in vivo in red ans the intersection between them in orange
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However, only 207 (out of a total of 931) stimulus-response circuits, corre-
sponding to almost all the pathways (20 out of a total of 23 modeled9) (repre-
sented in Table 4.7) sowed any coincident patterns of activation in response to
the several drugs tried. Almost half of the drugs tried (58 out of 132) caused
an identical eﬀect both in vitro and in vivo in at least one circuit of at least
one pathway.
Pathway Name Drugs
PPAR signaling pathway bendazac, benzbromarone, ben-
ziodarone, cloﬁbrate, fenoﬁbrate,
furosemide, gemﬁbrozil, simvas-
tatin, sulfasalazine, WY-14643
p53 signaling pathway colchicine, disopyramide, ethio-
nine, moxisylyte, nitrosodi-
ethylamine, propylthiouracil,
puromycin aminonucleoside,
quinidine
Citokine-Citokine receptor interaction diazepam
Apoptosis hydroxyzine, nitrofurantoin
Hedgehog signaling pathway
Cell adhesion molecules caﬀeine, aproxen, nitrofurazone,
tacrine, colchicine, gentamicin
Antigen processing and presentation ﬂutamide, puromycin aminonu-
cleoside
B cell receptor signaling pathway nimesulide, nitrofurazone, chlo-
ramphenicol, colchicine, mexile-
tine, gentamicin, hydroxyzine,
sulpiride
Melanogenesis doxorubicin, isoniazid
ERBB signaling pathway hydroxyzine, nitrofurantoin,
colchicine, ethionine, colchicine,
caﬀeine
WNT signaling pathway caﬀeine, ibuprofen
9See Table 4.1
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VEGF signaling pathway acetamidoﬂuorene, cyclophos-
phamide, danazol, diazepam,
ethambutol, ethinylestradiol,
ibuprofen, cyclosporine A, di-
azepam, ajmaline, ethinylestra-
diol, ethambutol, nitrofurantoin,
nitrofurantoin
Tight Junction caﬀeine, cisplatin, naproxen,
sulindac, ethionine, gentam-
icin, monocrotaline, puromycin
aminonucleoside
Jak-STAT signaling pathway diclofenac, disopyramide,
furosemide, ibuprofen, sulin-
dac
Fc epsilon RI signaling pathway colchicine, ethionine, gentam-
icin, penicillamine, valproic acid
Adipocytokine signaling pathway diclofenac, naphthyl isothio-
cyanate, naproxen, colchicine
Calcium signaling pathway ethionine, hydroxyzine, caﬀeine
Notch signaling pathway methimazole, naproxen
ECM-receptor interaction nifedipine
Gap junction carbon tetrachloride
T cell receptor signaling pathway colchicine, ethionine, gentam-
icin, penicillamine, valproic
acid, caﬀeine, disopyramide,
naproxen, sulindac, naphthyl
isothiocyanate, hydroxyzine,
coumarin
GnRH signaling pathway disopyramide, naproxen, iproni-
azid
Table 4.7: CAMDA results. Table showing the pathways with coincident
patterns of activation between in vitro and in vivo samples, in response to
several of the drugs tried.
The results in the context of the PPAR signaling pathway are represented in
Figure 4.21. The subpathway activated by: benzbromarone, cloﬁbrate, fenoﬁ-
brate, and WY-14643 is shown in orange; subpathway activated by: benzio-
90 CHAPTER 4. DATA AND RESULTS
darone, and sulfasalazine is shown in purple; andsubpathway activated by: ben-
dazac, benzbromarone, fenoﬁbrate, gemﬁbrozil, simvastatin, and WY-14643 is
shown in pink. The orange and purple subpathways produced the same func-
tional consequence: Lipid metabolism activation, and the pink subpathway
provoked Adipocyte diﬀerentiation.
Figure 4.21: Drugs showing the same behavior between the in vitro
and in vivo samples as represented in a pathway context. The sub-
pathway activated by: benzbromarone, cloﬁbrate, fenoﬁbrate, and WY-14643
is shown in orange; subpathway activated by: benziodarone, and sulfasalazine
is shown in purple; andsubpathway activated by: bendazac, benzbromarone,
fenoﬁbrate, gemﬁbrozil, simvastatin, and WY-14643 is shown in pink. The
orange and purple subpathways produced the same functional consequence:
Lipid metabolism activation, and the pink subpathway provoked Adipocyte dif-
ferentiation
Using pathways to assess drug responses has a number of limitations. Firstly,
there are drugs (half of the drugs tested here) that do not aﬀect the set of
modeled signaling pathways and therefore their eﬀects remain undetectable.
Secondly, in other cases, strong responses, which are mainly observed in vitro,
mask the induction or repression of common circuits that might be useful to
predict drug activity.
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However, despite these limitations, our results suggest that pathway models
can oﬀer an interesting alternative to other black box methods for drug ac-
tivity prediction. More detailed modeling of cell activity, including metabolic
pathways and other aspects such as regulation, protein interaction, etc., will
probably increase their predictive accuracy while also providing valuable infor-
mation on the mechanisms of drug action.
4.7 The PATHiWAYS tool
PATHiWAYS [89] web-tool (See ﬁgure 4.22) was developed in order to carry
out the special analysis approach developed in this thesis in the simplest and
most user-friendly way possible.
Figure 4.22: Main page of PATHiWAYS web-tool
PATHiWAYS is a web-based signaling pathway analysis and visualization
system that infers changes in signaling that aﬀect cell functionality from gene
expression values obtained in typical expression microarray case-control exper-
iments. This tool allows to the user to easily analyze microarray expression
data from ﬁve diﬀerent platforms, three for human and two for mouse (the
platforms available are shown in Table 4.8).
The user can use expression microarray raw data (.CEL ﬁles) or a rma
normalized expression matrix as input data. The analysis method developed
in this thesis is applied to these data given as experimental condition ﬁle in-
dicating which sample belongs to each condition. The user can choose the
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Specie Platform
Homo sapiens
Aﬀymetrix Human Genome U133 Plus 2.0 Array
Aﬀymetrix Human Genome U133A Array
Aﬀymetrix Human Genome U133A 2.0 Array
Mus Musculus
Aﬀymetrix Mouse Gene 1.0 ST Array
Aﬀymetrix Mouse Genome 430 2.0 Array
Table 4.8: Platforms which were modeled in PATHiWAYS tool
function used to summarize the probability of multiple genes being in a node
(mean, median, maximum, minimum and 90th, 95th and 99th percentiles), the
test applied (multilevel or Wilcoxon) and the pathways used to do the analysis
(from the ones modeled for each species).
The output is divided into three sections. A summary of the input data
for the analysis is shown in the ﬁrst one. The second one is a clickable index
of the selected pathways and the item summary. Here, the user can choose
the results will be shown in the last section. When summary item is clicked,
a table summarizing the results of all the pathways is shown in the lower
section. Nevertheless, if a pathway is clicked, the results of this pathway are
shown. These individual results are diﬀerent depending on the test selected. If
multilevel modeling is selected, the results consist of a table indicating the mean
and the conﬁdence interval of each subpathway in the pathway, a graphical
representation of this table and a pathway context representation of the results.
On the other hand, if the Wilcoxon test is selected, the results consist of a table
indicating the p-value and its FDR-corrected value for each subpathway in the
pathway and a representation of the pathway context results.
5Chapter
Other applications of the
method
"Science never solves a problem without creating ten
more."
 George Bernard Shaw
The methodology developed in this thesis was used to the develop of another
two tools: PATHiPRED[115] and PATHiVAR[143].
PATHiPRED (Section 5.1) is a web-tool for predicting discrete classes as
well as continuous variables from a microarray expression dataset. This web-
tool allows the user to create biomarkers associated with a certain disease and
predictors of continuous variables such as drug concentrations. This approach
was developed jointly with Dr. Alicia Amadoz as another application of the
methodology developed in this thesis. In this case, instead of comparing of
two classes, the modeling and subpathways probabilities estimation was used
to create discrete and continuous variable predictors.
PATHiVAR (Section 5.2) is a web-tool for visualizing and analyzing se-
quencing data in a pathway context. This tool allows the user to look for
the subpathways aﬀected by a certain genomic variation taking into account
the heredity assumed model and how harmful the variant is. This approach
was developed in the context of Rosa Divina Hernansaiz-Ballesteros Biotech-
nology's research project (RP) [144] and later in her Bioinformatics master's
degree research project (MRP)[145], both directed by Dr. Joaquin Dopazo and
myself. The approach uses the pathway modeling and the subpathway signal
transmission to asses the impact of genomic variants on diﬀerent functions.
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5.1 Predictors from sub-pathway probabilities
5.1.1 Abstract
The accumulation of a huge number of microarray datasets covering several dis-
eases aver the last decade has fostered in an active quest for disease biomarkers.
Initially, these biomarkers were genes selected according to their ability to dis-
criminate among the classes compared [146, 147, 148]. However, the biomarkers
found are not always reproducible across diﬀerent studies [149, 150, 151], usu-
ally because complex traits are not produced by only one gene, but by a set
of genes that jointly causes the disease [149, 152]. The set of genes implied
in the disease can vary across diﬀerent individuals, but the loss/gain of func-
tionality they provoke has to be shared between the diﬀerent individuals. This
premise has motivated recent approaches that propose subnetworks as biomark-
ers with better predictive power than single-gene biomarkers [153]. Some of
these approaches have produced eﬀective biomarkers for diﬀerent diseases such
as: diabetes [154], Alzheimer [155] and diﬀerent types of cancer as breast can-
cer [156, 157, 158], ovarian cancer [159, 160, 161], glioblastoma [159, 87] or
prostate cancer [162]. These sub-network structures have also been used to
predict treatment responses [163] as well as to search for drug targets [164].
The approach presented here dissects pathways into subpathways and checks
these as possible biomarkers for distinguishing between diﬀerent classes (dis-
crete variables) or to predict a continuous variable. In addition, in the same
way as the PATHiWAYS approach, expression values are transformed into acti-
vation probabilities in order to make measurements between genes comparable.
That is, the measurement used to perform predictions in this platform is the
probability that a subpathway is active.
5.1.2 Material and Methods
Two approaches can be distinguished according the type of variable being pre-
dicted: class prediction (discrete variables) and continuous variable prediction.
The input to both methods is the activation probability of each subpathway
considered. To calculate these probabilities from expression data they were
normalized using RMA, as explained in 3.2.1. The probability of subpathway
activation was then estimated following the work-ﬂow developed in this thesis
(See Figure 3.1). In this case, the subpathway probabilities are not comparable
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between each other because of the high number of nodes the low probabilities1.
To solve this problem, the subpathway probabilities were corrected using the
number of subpathway nodes to obtain comparable activation probabilities.
Class prediction
First, subpathways showing no variability across the compared classes were
discarded in order not to introduce noise in the model. These subpathways
cannot help to distinguish between the classes being compared because they
behave the same in all the classes, so deleting them helps to reduce noise in the
model as well as reducing the dimensionality of the input data and therefore
the computing time.
Feature selection was then performed using the Correlation-based Feature
Selection (CFS) method [165]. Class prediction was carried out using subpath-
way activation probability matrices. The algorithms used for prediction are:
K-Nearest neighbor (KNN), Random Forest (RF) [166] and Support Vector
Machine (SVM) [116] and the parameters used to evaluate the classiﬁcations
obtained were: accuracy, Mathews correlation coeﬃcient (MCC), root mean
square error (RMSC) and the area under the curve (AUC); all of these meth-
ods were implemented in the Babelomics platform [136].
To test our approach, datasets for two cancers were employed, both down-
loaded from the Gene Expression Omnibus (GEO) public repository at the
National Center for Biotechnology Information (NCBI) [26]. The ﬁrst one
(GSE9476) was related to acute myeloid leukemia (AML) and contained data
for 26 healthy donors and 26 AML patients [114]. The second one was a breast
cancer dataset (GSE27562) composed of 31 normal samples and 31 malignant
peripheral blood mononuclear cells (PBMC) samples[113].
Continuous variable prediction
In continuous variable prediction, subpathways which do not vary are not
deleted, and so all the subpathway probabilities are used to perform a SVM re-
gression selecting the best γ and cost parameters from the diﬀerent values tested
(10, and 100 cost values; and 10( − 6), 10(−5), 10( − 4), 10(−3) γ values), by
optimizing the mean squared error of the model with a 10-fold cross-validation.
If required, feature selection was performed using the CFS method [165].
1This point was not a problem in PATHiWAYS approach, because in that case the
subpathway probabilities were compared 2 at time and so no bias caused by the number of
nodes belonging to the subpathway could exist.
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To test this approach, studies which give the concentration at which drug
responses reach 50% (IC50) absolute inhibition were used. Two large datasets
were used for this purpouse, one from the Cancer Genome Project (CPG) [167]
(E-MTAB-783) and the other from the Cancer Cell Line Encyclopedia (CCLE)
[168] (GSE27562). These datasets provide information about the IC50 variable
for 138 drugs and 661 cell lines which correspond to 17 cancers in the case of
CPG and 24 drugs and 493 cells lines corresponding to 24 cancers in the case
of CCLE.
5.1.3 Results
Use of signaling circuit activation probabilities in the context of
prediction
In order to determine how useful these mechanism-based biomarkers are for
prediction purposes, these prediction algorithms where tested in the context of
gene expression in the AML and breast cancer datasets (Subsection 5.1.2). The
data were normalized and transformed into subpathway activation probabilities
as previously described (Section 3.2). Next, feature selection was carried out
using CFS and the selected biomarkers were used to predict the class (case or
control) to which samples in each dataset belong to. The K-Nearest neighbor
(KNN), Random Forest (RF) and Support Vector Machine (SVM) algorithms
were used for this analysis, and the accuracy of the prediction was evaluated
using: accuracy, Mathews correlation coeﬃcient (MCC), root mean square er-
ror (RMSC) and the area under the curve (AUC). The results are shown in
table 5.1. All the methods gave diﬀerent accuracy results but showed an excel-
lent potential to predict the proposed mechanism-based biomarkers. However,
SVM produces the best predictions in all of the accuracy parameters consid-
ered, therefore it was used to carry out all the subsequent predictions, using
the activation status of the signaling circuits as features. In addition SVM also
has the advantage that it can predict continuous parameters.
Performance of the classiﬁcation method using mechanism-based
biomarkers
To demonstrate that mechanism-based biomarkers are an eﬃcient way to pre-
dict discrete classes, a scenario in which no discrete variables (classes) exist
was used to test the predictor's ability to diﬀerentiate between two (inexistent)
classes. Two diﬀerent approaches were tested: 1)taking a random sample and
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Dataset KNN RF SVM
Accuracy 0.86-0.89 0.90-0.92 0.99
Breast cancer MCC 0.74-0.79 0.81-0.83 0.98
RMSC 0.29-0.32 0.31 0.04
AUC 0.97-0.98 0.98 0.99
Accuracy 0.88-0.89 0.92-0.95 0.96
AML MCC 0.76-0.78 0.84-0.90 0.92-0.93
RMSC 0.27-0.30 0.31 0.10-0.11
AUC 0.94 0.98 0.96
Table 5.1: Results from the prediction algorithms used on the GBM
dataset. MCC is the Mathews correlation coeﬃcient, RMSC is the root mean
square error and AUC is the area under the curve
generating a dataset from it by adding diﬀerent levels of noise; and 2) using a
real dataset made up of diﬀerent samples in the same condition. To generate
the ﬁrst dataset, a random sample from the Aﬀymetrix Human Genome U133
Plus 2.0 Array dataset used to model the expression of the associated probesets
(Section 3.2.1), was selected. Random noise was then added to generate N dif-
ferent samples, which were randomly assigned to two classes. 1000 simulations
were carried out with diﬀerent noise levels (SD= 0.1, 0.075, 0.05, 0.025 and
0.01 and diﬀerent sample sizes (N=20, 50, 100 and 200). The real dataset was
the same dataset used to perform the false positives analysis (Section 4.3), and
consisted of 237 samples of Acute Myeloid Leukemia (AML)[110]. Figure 5.1
shows the distribution of accuracy values obtained in both simulated scenarios.
In both cases the average value is slightly over 0.5, i.e. equivalent to a random
choice between two equal possibilities. Therefore, the ratio of false positives
can be considered negligible.
Prediction of IC50 values for cancer drugs
Because mechanism-based biomarkers are eﬃcient at predicting discrete classes,
we also explored their eﬃciency in predicting a continuous value. To test how
oue approach behave when predicting continuous variables, the CPG dataset
was used to train the predictors and CCLE dataset was used to validate them
(Section 5.1.2). Both datasets were ﬁltered to obtain data a total of 317 cell
lines, 12 cancers and 7 drugs that are common them both. The CGP data were
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Figure 5.1: Estimation of the false positives ratio. Accuracy (cross-
validation) for the two simulated classes (discrete variable) scenarios: A) classes
made with randomly partitioning a pediatric AML dataset of identical AML
patients and B) simulated array probes. The cross-validation values are slightly
higher than 0.5, that is, indicating correctAccuracy (cross-validation) for the
two scenarios of simulated classes: A) classes made with random partitions of
a pediatric AML dataset of identical patients and B) simulated array probes.
The cross-validation values are slightly higher than 0.5, indicating correct class
assignation by pure chance.
normalized and these normalized gene expression values were transformed into
signaling subpathway activation probabilities as previously described. Finally,
a predictive model was obtained for the CGP data after SVM-regression, and
this data was used to predict the IC50 values of the CCLE dataset. Figure 5.2
shows the agreement between the predicted a real values. There was a highly
signiﬁcant positive correlation (r=0.709, p=8.98x10-193) between the predicted
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Cancers Paclitaxel AZD6244 Nilotinib PLX4720 Sorafenib Erlotinib Lapatinib
Lung 2.99 3.59 2.77 3.85 2.82 5.08 3.87
Haematopoietic-lymphoid 2.98 2.68 2.42 3.33 3.05 4.88 3.89
Bone 3.96 3.01 NA 2.5 2.78 3.61 3.96
Skin 1.63 4.71 2.02 5.3 1.19 2.66 3.22
Ovary NA 3.33 3.18 3.77 NA NA NA
Central nervous 2.67 4.51 2.83 3.66 2.29 2.41 2.47
Pancreas NA 2.08 4.34 3.85 NA NA NA
Soft tissue 0.64 3.01 2.88 2.88 3.77 3.99 3.59
Breast 2.23 3.87 3.17 NA 3.67 5.19 5.28
Upper aerodigestive tract 0.52 2.3 2.73 NA 1.86 2.17 1.49
Kidney 1.22 NA 2.88 NA NA NA NA
Thyroid NA 2.51 2.58 1.71 NA NA NA
Table 5.2: RMSE per cancer type and drug in the CCLE dataset. NAs
appears when not enough data were available.
and real IC50 values measured in the CCLE dataset which clearly proves the
validity of the prediction framework we propose here. Figure 5.3 shows the
predicted IC50 values and the corresponding real IC50 values available for the
CCLE dataset averaged by tissue. Both the predicted and real IC50 values
were compared by estimating the root mean square error (RMSE) (Table 5.2).
While there are some discrepancies, the global RMSE of 3.31,which includes all
cancers and drugs, demonstrates that the prediction accuracy was reasonable.
Speciﬁc cancers and drugs for which the prediction is especially good are: the
upper aerodigestive tract (RMSE=0.52) and soft tissue (RMSE=0.64) treated
with Paclitaxel.
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Figure 5.2: Predicted versus actual CCLE IC50 values.
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Figure 5.3: CCLE predicted and observed IC50 values per cancer and
drug.
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5.1.4 PATHiPRED tool
In the same way as for PATHiWAYS, the developed methodology was imple-
mented in a web-tool called PATHiPRED[115] located at the same URL as
PATHiWAYS2. PATHiPRED diﬀerentiates between two classes or predicts a
continuous variable using the activation probabilities from stimulus-response
sub-pathways calculated by PATHiWAYS methodology. PATHiPRED per-
forms a SVM modelling with cross-validation and the results include details
about the prediction model, the statistical parameters used to assess the good-
ness of the model, the confusion matrix of the prediction, the activation proba-
bilities matrix, the mechanism-based biomarkers and pathways graphs with the
selected sub-pathways highlighted. Moreover, the prediction model obtained
can be applied to a new dataset within PATHiPRED web tool.
The program use CEL ﬁles that are transformed into subpathway activa-
tion probabilities as input to derive predictions about conditions under study.
Additionally, a matrix (samples x probabilities) can be saved which can subse-
quently used in other programs to derive predictors with other algorithms (for
example in Babelomics[136]), if desired.
5.1.5 Prediction of molecular phenotypes - The Dialogue for
Reverse Engineering Assessments and Methods
(DREAM) challenge
DREAM (Dialogue for Reverse Engineering Assessments and Methods) sci-
ence challenges are a non-proﬁt and open eﬀort to pose fundamental questions
about systems biology and translational medicine. Participants propose dif-
ferent solutions to a common problem and all the contributions are shared to
improve everyone's scientiﬁc knowledge. We participated in the DREAM Tox-
icogenetics Challenge to build models of cytotoxicity as mediated by exposure
to environmental toxicants and drugs. In our case, DREAM provided a dataset
containing estimations of cytotoxicity as measured in lymphoblastoid cell lines
derived from 884 individuals following in vitro exposure to 156 chemical com-
pounds (Figure 5.4). Given these data, two diﬀerent subchallenges were given:
Subchallenge 1 Predict interindividual variability in in vitro cytotoxicity
based on genomic proﬁles of individual cell lines. For each compound,
participants will be challenged to predict the absolute values and relative
2Just a bottom to run PATHiPRED was added to the same web-tool
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ranks of cytotoxicity across a set of unknown cell lines for which genomic
data is available.
Subchallenge 2 For each compound, predict the concentration at which me-
dian cytotoxicity would occur, as well as inter-individual variation in
cytotoxicity, described by the 5-95th%ile range, across the population.
Each prediction will be scored based on the participant's ability to pre-
dict these two parameters within a set of compounds excluded from the
training set.
Figure 5.4: Data provided to DREAM Toxicogenetics Challenge
We participated in the second subchallenge. The data was used to estimate
the probabilities in signal transduction for all the stimulus-response circuits
of each signaling pathway starting from gene expression values. These proba-
bilities were used in a SVM -regression with k-fold cross-validation to obtain
a prediction model. Only samples for which RNA-seq data is available were
used for this predictive approach. This data measures the quantity of mRNA
present in the sample, in the same way that microarrays do. However, in this
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case it was not possible to deﬁne the background data because there were not
enough data available. Therefore, we transformed the RNA-seq data in a [0,1]
interval, where genes with higher mRNA expression have a higher value in
the transformation and vice versa. Thus, using this value as a probability,
we estimated the probabilities of signal-transduction subpathways activation.
These estimated probabilities were used as mechanism-based biomarkers in the
prediction algorithm instead of the raw gene expression values.
Using the approach proposed in this thesis, the expression values of 2,585
genes included in human signaling pathways were recoded into 1,126 signal
transduction probabilities, corresponding to all the signaling circuits that can
be deﬁned in the 26 pathways analyzed.
RNA-seq count data were available for 192 individuals, using these data, we
ﬁtted a regression model for each drug. First, circuits whose activation proba-
bility was constant across all individuals were discarded as potential biomark-
ers. Then, the remaining biomarkers were ﬁltered according to each compound
by CFS using the FSelector R library [165]. Next, SVM -regression we per-
formed with the selected circuits using the e1071 R library [169] selecting the
best γ and cost parameters from among the diﬀerent values tested (10 and 100
for cost values; 10−6, 10−5, 10−4 and 10−3 for γ values), by optimizing the
mean squared error of the model with a 10-fold cross-validation.
The results uploaded by diﬀerent teams were ranked according to diﬀerent
metrics:
• The mean ranking PC: average of the rankings computed using PC based
on the predicted versus observed median response (PCm) and the pre-
dicted versus observed interquantile distance (PCq)
• The rank PC: rank of mean ranking PC
• The mean ranking SC: average of the rankings computed using SC based
on the predicted versus observed median response (SCm) and the pre-
dicted versus observed interquantile distance (SCq)
• The rank SC: rank of mean ranking SC
• The mean ranking: average of mean ranking PC and mean ranking SC
• The rank: rank of mean ranking
According to these metrics, our team was located 85/99. A limitation of
our NIEHS-NCATS-UNC DREAM Toxicogenetics Challenge prediction results
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was that RNA-seq data were not available for 167 individuals in the submission
dataset. Consequently, our global results were penalized in the scoring criteria
because more than a half of the ﬁnal samples were missing. However, the
subset of 97 individuals for which RNA-seq data were available had a root
mean square error (RMSE) lower than 0.3, which was obtained in the cross-
validation process of the best models calculation.
The results of this challenge were published in Nature Biotechnology as a
paper describing the results analysis and broadly applicable insights that arose
from the DREAM Toxicogenetics Challenge [170].
5.2 Pathway analysis of structural genomic data
5.2.1 Biological introduction
A biological introduction is ﬁrst required here because this approach is built
upon diﬀerent biological concepts.
Gene expression is the ﬁnal consequence of transcription of genome's in-
formation (Section 1.2). Therefore, a variation in the DNA information due a
mutation can produce a change in gene expression and consequently a potential
protein production failure that can provoke a disease.
In 2007, J.Craig Venter[22]3 and Watson[172] quasi-simultaneously pub-
lished a complete human genome sequence. These studies were followed by an-
other publications that jointly increased our knowledge of gene variation[173].
Analysis of these human genomes gave rise to two main conclusions: variants
are more common than expected and the association between a variant and a
determined pathology is not always straightforward.
Variations in the genome are identiﬁed using DNA sequencing techniques.
Techniques for genome sequencing have taken great strides forward to allow a
huge quantity of samples in a relatively short period of time. These advances
have motivated projects to sequence a huge number of individuals (or popula-
tions) who share a particular characteristic such as certain disease (e.g diﬀerent
types of cancer).
Molecular medicine studies variations in the genome that provoke diseases.
These are deﬁned as modiﬁed versions (from one to several nucleotides) when
compared to the original gene. There are diﬀerent types of variations in the
genome (Figure 5.5).
3In the context of Human Genome Project[171] (HGP)
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Figure 5.5: Types of genomic variants (Figure extracted from [173])
Single nucleotide variants are DNA sequence variations in which a single nu-
cleotide (A, T, G or C) is altered. Insertiondeletion variants (indels) oc-
cur when one or more base pairs are present in some genomes but absent in
others. Block substitutions describe cases in which a string of adjacent nu-
cleotides varies between two genomes. An inversion variant is one in which
the order of the base pairs is reversed in a deﬁned section of a chromosome.
Copy number variants occur when identical or nearly identical sequences are
repeated in some chromosomes but not others.
The consequence of a variant in the production of the associated protein
depends on both: the region of the gene where the variant is located (Table
5.3) and the type of aminoacid change (Table 5.4). If a variant is located in
a intergenic region, the resulting protein is not aﬀected, because only exons
are transcribed, but if it is located in a exonic region, it is possible that the
production of the protein will be aﬀected. On the other hand, if the change in
nucleotides does not aﬀect the resulting aminoacid4 (synonymous variant), the
protein sequence is not aﬀected and the protein remains functional.
In addition, there are some scores that indicate how harmful the variant is
to the structure of the resulting protein:
• Sorting Intolerant From Tolerant (SIFT)[175]: Predicts whether an amino
acid substitution aﬀects protein function. Its prediction is based on the
degree of conservation of amino acids residues in the sequence alignments
derived from closely related sequences.
4See table 1.1
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Annovar code Region
UTR3 3'UTR region
UTR5 5'UTR region
exonic coding region
splicing splicing site
ncRNA non-coding RNA
intronic intronic region
upstream region towards the 5' end of the strand
downstream region towards the 3' end of the strand
intergenic intergenic region
Table 5.3: Biological consequences of the diﬀerent types of variants
depending on the region where the nucleotide is located. This coding,
indicated by Annovar [174], is used to annotated the consequence of the DNA
variations.
• Polymorphism Phenotyping (PolyPhen)[176]: Predicts the possible im-
pact of an amino acid substitution on the structure and function of a
human protein using straightforward physical and comparative consider-
ations.
Deleterious variants also depend on which heredity model is taken into
account. Diploid organisms, such as humans, contain two copies of each gene,
one on each strand, corresponding to the paternal and maternal alleles. Based
on the occurrence of the mutation in each copy, two main heredity models
can be deﬁned: dominant and recessive. In the dominant model, a gene is
considered to be non-functional if exists a deleterious variant in almost one
copy5 of the gene (heterozygous gene). Otherwise, in the recessive model, a
gen is considered to be not functional if both copies of the gen have a variant
(homozygous gene). In this case two diﬀerent options could be considered:
homozygous or compound heterozygous gene. In the ﬁrst case, there must
exists a variant in both copies of the gene in order to consider it as deleterious.
In the case of compound heterozygous, a gene is considered as non-functional
if exist almost two positions of the gene having a variant.
5DNA is a double stranded molecule, so it produces two copies of the gene, one for each
strand
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Annovar code Aminoacid change
frameshift insertion insertion of one or more bases that change
the reading frame
frameshift deletion deletion of one or more bases that change
the reading frame
frameshift block substitution block substitution of one or more bases
that change the reading frame
stopgain variant that provoke a stop codon creation
stoploss variant that provoke a stop codon deletion
nonframeshift insertion insertion of one or more bases that do not
change the reading frame
nonframeshift deletion deletion of one or more bases that do not
change the reading frame
nonframeshift block substitution block substitution of one or more bases
that do not change the reading frame
nonsynonymous SNV variant that do not cause a change in the
resulting amino acid
synonymous SNV variant that cause a change in the resulting
amino acid
unknown unknown function of the variant
Table 5.4: Biological consequences of the diﬀerent types of variants
depending on the aminoacid's change. This coding, as indicated by An-
novar [174], is used to annotate the consequence of DNA variations.
5.2.2 Motivation
The approach presented here was developed in the context a Biotechnology's
research project (RP) and later in the Bioinformatics master's degree research
project (MRP), both undertaken by Rosa Divina Hernansaiz Ballesteros, and
directed by Dr. Joaquin Dopazo and myself[144, 145].
The motivation for developing this approach was to study variations in
healthy people from several populations in the context of signaling pathways.
Their structure is used to look for diﬀerences in terms of the functionality of
signaling subpathways in the diﬀerent populations and to study the robustness
of disrupted functional subpathways against variants in a healthy population.
Therefore the objectives of this work were:
• To compare the functional consequences of variants in healthy people
between diﬀerent populations.
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• To study the robustness of variants in terms of loss-of-functionality in
signaling subpathways.
• To compare functional pathways in diﬀerent tissues according to the dele-
terious variants that map to them.
• Implement a web-tool to visualize the predicted changes in signaling
transduction probabilities across the diﬀerent signaling pathways.
The tool provided from this work was recently published [143] in Nucleid
Acids Research and another paper covering the ﬁrst two objectives is under
preparation.
5.2.3 Material and Methods
The data used in this project describe the genomes of healthy people from dif-
ferent populations in 1000 Genomes Project [177] database. The 1000 Genomes
Project [177] aims to build a resource to help to understand the genetic con-
tribution to disease and the relationship between genotype and phenotype. it
includes samples from healthy donors from 14 populations that can be classiﬁed
into 4 super-populations (Table 5.5)
Data was download from the 1000 Genomes Project web-page and the func-
tional consequences of variants were annotated by using Annovar [174] (See
Tables 5.3 and 5.4), to obtain 14 ﬁles (one for each population) that contain
information about the variants mapping all the 980 genes included in the set of
selected pathways6. Once the variants are annotated, they have to be classiﬁed
into deleterious and non-deleterious, using diﬀerent ﬁlters.
The initial work (RP) only took the functional consequences of the variants
and the heredity model considered into account.We compared healthy popu-
lations and analyzed the robustness of the signaling pathways in the face of
aleatory genome variations for the three heredity models. However, both the
dominant and recessive model classiﬁcation was too restrictive, and so com-
pound heterozygous gene modelling is considered to be best represent a com-
mon hereditary model. Variants annotated as splicing, stoploss, stopgain and
frameshift were considered to be deleterious variants.
The analysis performed for the MRP not only took variant information into
account, but also information about gene expression in diﬀerent tissues as a
ﬁlter for KEGG pathway information, thus integrating both the genomics and
6This set is the same as the one indicated in Section 4.1
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Super-population Population abb
Europe
Utah residents with Northern and Western
European ancestry
CEU
Toscani in Italy TSI
British in England and Scotland GBR
Finnish in Finland FIN
Iberian populations in Spain IBS
Africa
Luhya in Webuye LWK
Yoruba in Ibadan YRI
African Ancestry in Southwest US ASW
East Asia
Han Chinese in Beijing CHB
Japanese in Tokyo JPT
Southern Han Chinese CHS
Americas
Puerto Rican in Puerto Rico PUR
Mexican Ancestry in Los Angeles MXL
Colombian in Medellin CLM
Table 5.5: Populations considered in the 1000 Genomes Project. This
table shows its classiﬁcation into super-populations as well as the abbreviations
for these populations
trancriptomics information. Once genes are selected as expressed in the tissue,
deleterious variants are selected by their functional consequence: splicing, sto-
ploss, stopgain, frameshift and nonsynonymous. In this case, nonsynonymous
variants are classiﬁed as potentially deleterious, but are only considered as dele-
terious if they have an associated SIFT value less than 0.05 and a PolyPhen
value greater than 0.857.
KEGG nodes include information for more than one gene (Section 3.1.1)
acting in diﬀerent tissues. To asses which genes are speciﬁcally act in each
tissue data from [142], including 1,033 samples, or expression data including
66 normal tissues (Figure 5.6), were used.
These data were downloaded and normalized using the RMA[14] method
(See Section 1.2.1). Genes were classiﬁed into active/inactive in the tissue using
the presence-absence calls with negative probesets (PANPs)[178] approach that
7These values are the recommended by the authors of the respective papers
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Figure 5.6: Number of samples for each tissue in [142]. Diﬀerent tissues
have a diﬀerent number of samples ranging from 1 to 43.
uses PM measurements to establish the presence or absence of their activity.
This ﬁlter drastically reduced the number of subpathways considered in the
analysis, because only subpathways in which all the nodes were active in the
tissue were took into account.
Once the variants are classiﬁed into deleterious or non-deleterious, this in-
formation is used to classify genes as functional or non-functional. A gene is
deﬁned as functional if it has a 100% probability of producing a functional pro-
tein, that is, genes are functional if they do not have any deleterious variable
mapping to them. Using this coding system in the context of the methodol-
ogy developed in this thesis, we could assume that if a gene is functional, it
has a 100% probability of transmitting the signal along the network (so it can
be considered as completely active), and if not, it can be considered as non-
active with a 0% of probability of transmitting the signal along the network.
Therefore,
p =
{
1 Functional gene
0 Non-Functional gene
After applying this simpliﬁcation is done, the rules in section 3.4 can be
applied in order to calculate the 'probability' of a node being functional and
ﬁnally the 'probability' of a sub-pathway being functional. In this approach,
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the 'probabilities' considered are binaries (0 or 1) so, the rules for transmitting
the signal along the sub-pathways could be summarized in terms of logical
operations (Figure 5.7). In this way, a node is considered as functional if any
of the genes mapping to it are considered functional, a complex is considered
functional if all nodes in it are functional, a path is considered functional if all
nodes and complexes that compose it are functional and ﬁnally, a subpathway
is considered functional if any of the paths comprise it are functional.
GENE NODE COMPLEX PATH
SUB-
PATHWAY
ANY ALL ALL ANY
Figure 5.7: Pipeline for propagating binary signals through a sub-
pathway. It is based on gene classiﬁcation into deleterious or non-deleterious,
functional or non-functional, and ﬁnally active or inactive in the tissue samples
download from the 1000 Genomes Project using the presence-absence calls with
negative probesets (PANPs) approach to make PM measurements.
These rules were applied for each individual in each population in order to
dissect if each sub-pathway should be considered as functional or not, to pro-
duce a binary matrix summarizing the information about the 656 sub-pathways
in the 1,167 individuals of the 14 populations considered8. Once this matrix is
obtained this information can be used in two diﬀerent approaches:
1. Comparison between healthy populations in terms of functionality of the
sub-pathways
2. Evaluation of the functionality of the diﬀerent sub-pathways against ran-
dom variants.
We compared the populations using the Barnard test [?] on all of the sub-
pathways and by correcting by multiple testing with the False Discovery Rate
(FDR). Evaluation of the robustness of the sub-pathways against random vari-
ants was done by simulating random variants in the 980 genes under study by
using the frequency of variation as in the real data multiplied by 100 times.
This simulated data is put through the pipeline shown in Figure 5.7 to obtain
100 simulated sub-pathway functionality matrices. The results obtained are
graphically then compared with the real ones.
8In the case of the MRP this analysis was done 66 times, one for each tissue.
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5.2.4 Results
Comparison between healthy populations
As an example of the diﬀerences between populations in terms of functional sub-
pathways, some sub-pathways in the Melanogenesis Signaling Pathway appear
to be diﬀerentially functional between African, Asian and European popula-
tions (Figure 5.8): YRI individuals has the orange subpathway as not functional
and the green one appears as non-functional in comparison between african and
asiatic individuals. Genes in these sub-pathways are included in a study[179]
that relates them to diﬀerent pigmentation phenotypes in the diﬀerent popu-
lations.
Figure 5.8: Sub-pathways that are diﬀerentially functional between
diﬀerent super-populations derived from the 1000 Genomes Project in the
because of the presence of variants in the Melanogenesis pathway. YRI indi-
viduals has the orange subpathway as not functional and the green one appears
as non-functional in comparison between african and asiatic individuals.
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Comparison between diﬀerent tissues
An interesting result came from analyzing of the behavior of the diﬀerent sub-
pathways in the context of tissue development. For example, we compared
the expression patterns and variants in lung tissue from three diﬀerent dif-
ferentation stages: embryonic, fetal and adult (Figure 5.9), and showed that
diﬀerent subpathways were functional at diﬀerent stages of development, thus
highlighting how signals change throughout the development processes
(a) Embrionic Lung (b) Fetal Lung
(c) Adult Lung
Figure 5.9: Evolution of lung tissue in terms of functional sub-
pathways
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Pathways' robustness
Regarding to the robustness of sub-pathways against random variants, the
study was done in all populations giving similar results. In Figure 5.10 results
with CEU population are shown. Results with real data are represented in
red and results using simulated data are represented in black (join with their
conﬁdence intervals). We can observe that there are pathways which have all
its subpathways non-functional (e.g.Notch signaling pathway) and other which
have all its subpathways functional (e.g. Fc Epsilon Ri signaling pathway).
From this analysis we can conclude that the functionality of the subpathways
changes when comparing real and simulated data which have random variants.
As an example, in the Fc Epsilon Ri signaling pathway, real data show all
subpathways as functional, but simulated data shows a lower functionality in
the same subpathways.
Figure 5.10: Results of simulations compared with real data considering
recessive with compound heterozygous heredity model. Results with real data
are represented in red and results using simulated data are represented in black
(join with their conﬁdence intervals)
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PATHiVAR tool
The PATHiVAR web-tool[143] (Figure 5.11) estimates the functional impact
that mutations have over the human signaling network. PATHiVAR analyses
VCF ﬁles, extract the deleterious mutations, locates them in the signalling
pathways in the selected tissue (with the appropriate expression pattern) and
provides a comprehensive, graphic and interactive view of the predicted signal
transduction probabilities across the diﬀerent signalling pathways.
Figure 5.11: Main page of PATHiVAR analysis tool
The output of this tool is a table indicating all the pathways whose function
was signiﬁcantly aﬀected in their functionality as well as a representation of
these data in a pathway context in the same way the PATHiWAYS tool does.
6Chapter
Discussion
Understanding the role of genetics in disease is now a hot topic in medical
research. Some diseases are provoked by a single gene, but other complex dis-
eases, such as cancer, are caused by the malfunction of a set of genes although
the speciﬁc genes involved can change depending on the individual aﬀected.
This can be explained because diﬀerent genes share functionality and/or are
implicated in the same pathway. The approach presented on this thesis di-
rectly relates to expression data, i.e. measuring genotype, by the gain/loss
of cell functionalities in a pathway context. This allows researchers to relate
the changes in gene expression due to a speciﬁc diseases, with changes in the
pathway functionality.
The study of gene expression data from control-case experiments in a path-
way context is broadly studied by Bioinformatics. There are several methods
that estimate the impact of a certain condition on a pathway context1. These
methods can be divided into four types, or generations, where new generation
has been developed in order to overcome the limitations of the previous ones.
The most recent set of methods are termed subpathway-based approaches
and the method developed here is included in this generation. SB-methods
solve most of limitations of the previous methods; they use expression data
as well as pathway structure to estimate the impact of a disease, taking into
account the relationships established between the diﬀerent elements of the path-
way. They do not describe the impact of the whole pathway, but rather, they
deﬁne pathway substructures called subpathways. These structures allow the
researcher to focus on the speciﬁc part of the network aﬀected by the disease.
However, these methods do still present some limitations, and the approach
presented in this thesis is attempt to address these issues.
The ﬁrst limitation is a result of the way pathways are modeled. The
pathways in the KEGG contain information about some speciﬁc characteris-
1For a detailed explanation of pathway analysis methods see section 1.5
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tics that must be taken into account in the analysis of this data, as described
in on section 3.1. There are two concepts that are usually dismissed in almost
all pathway analysis methods: groups of genes that encode scaﬀold proteins,
and the diﬀerent nature of the relationships established between gene network
nodes. Groups are considered as separate nodes in the current pathway analysis
methods. However, they represent a set of nodes that have to act together to
propagate the signal, i.e. they are considered as independent when in fact they
have to act together for the signal to pass. Regarding the nature of the diﬀerent
relationships, they can be classiﬁed as activations and inhibitions, and the con-
sequence of each of these is diﬀerent in terms of signal propagation. Activators
enhance the proliferation of the signal along the network while inhibitors stop
it. Therefore, not considering the diﬀerent eﬀects in that these relationships
have on either enhancement or diminishment of signal propagation (as in most
current pathway analysis methods) creates error.
Another limitation of the previous methods is the lack of interpretability
of the results obtained. The jump from studying pathways to studying sub-
pathways came from the attempts to accounts for the fact that pathways are
structures which do not have well-deﬁned limits, i.e. each database deﬁnes
pathways from diﬀerent points of view, so the boundaries between them are
arbitrary. In the KEGG pathway database, with several diﬀerent functionali-
ties are associated with the same pathway, for example, the Apoptosis pathway
includes subpathways that point both to apoptosis and to the cell cycle, which
are clearly opposing functions. Therefore, deﬁning subpathways as cliques or
sub-graphs, which include several terminal nodes, produces a results which in-
cludes several and opposite functions included in the same subpathway, thus
making a clear interpretation of the data obtained from them impossible.
Finally, it is very important to give the methodology developed in this
thesis to the research community in an user-friendly form. Most of the previous
methods provide their approach in R language, which drastically reduces the
number of researches that are able to use it, because it is too technical for users
who are not experts in this speciﬁc ﬁeld.
All of these limitations have been overcome by our method: we model
KEGG pathways according their underlying biology and; diﬀerent relation-
ships are taken into account when calculating the signal propagation along the
network. We also created a user-friendly web-tool PATHIWAYS, which is pro-
vided in the following website http://pathiways.babelomics.org/. Another
two tools, PATHiPRED and PATHiVAR, which model pathways information
and how the signal is transmitted along the network in the same sense that the
approach proposed here, show the utility of this modeling.
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Nevertheless, the proposed approach still presents some limitations. The
most importnat of which is that only a few signaling pathways can be modeled.
This is, mainly because the existence of loops, and because metabolic pathways
cannot be modeled in this way. Therefore in future work it is important to take
this loops into account when ﬁnding ways to model how signal is transmitted
along the network. This not an easy problem, because, by deﬁnition, this type
of data analysis considers data from a ﬁxed time point, but loops represent
dynamic behaviors. Another limitation of this method is that the estimated
subpathway probabilities lack biological meaning, they only make sense for the
purposes of comparison. The diﬀerent lengths of the paths and the methods
of signal transmission along the network make it diﬃcult to interpret the raw
estimated probability.
In conclusion, the method developed and described in this thesis improves
upon the existing methods for subpathway analysis in many ways, but still
has some limitations. Thus, further work will be required to overcome these
limitations. Future work should also aim to include more microarray platforms
and pathway databases, perhaps even to give the user the opportunity to upload
their own network annotations. Finally, future work building upon the method
presented here chould aim to improve the test used to compare the data so
that is more compatible with this type of data and includes the structure of
the data used in its calculation algorithm.

7Chapter
Conclusion
• Probe set behavior for six Aﬀymetrix microarray platforms
were modeled. Concretely, three platforms for human, two for mouse
and one for rat were used. This database for probe set behaviors is the
core to calculate probe set activation probabilities.
• Pathway models representing the underlying biology were ob-
tained from KEGG database. This task includes the deﬁnition of
proper biologically oriented deﬁnitions of the diﬀerent types of both,
nodes and edges. Also, sub-pathway deﬁnition oriented to functionali-
ties provided by KEGG is a clear advantage of the proposed model.
• A new method for analyzing sub-pathway diﬀerential activa-
tion behavior between two conditions was developed. This ap-
proach, called PATHiWAYS, overcomes most of the limitations of pre-
vious methodologies. PATHiWAYS can be used to estimate which sub-
pathways in a pathway network are diﬀerentially more active/inactive
between two conditions by using expression data. This new methodology
probed its utility with the analysis of real data.
• A web-tool was implemented to analyze user data and provide a
easy graphical interpretation in a pathway context. This web-tool
allows to upload both raw or normalized data and provides numerical and
graphical results of the comparison between to experimental conditions.
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AChapter
Modeled KEGG pathways
In this chapter modeled pathways for Homo sapiens are represented joined
with its representation in KEGG database. Pathways of other species are
quite similar, and can be observed in PATHiWAYS web-tool [89].
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144 APPENDIX A. MODELED KEGG PATHWAYS
Pathway name Reference
PPAR signaling pathway Figure A.1
ErbB signaling pathway Figure A.2
Calcium Signaling pathway Figure A.3
Cytokine-cytokine receptor interaction Figure A.4
Chemokine signaling pathway Figure A.5
Neuroactive ligand-receptor interaction Figure A.6
p53 signaling pathway Figure A.7
mTOR signaling pathway Figure A.8
Apoptosis Figure A.9
Wnt signaling pathway Figure A.10
Notch Signaling pathway Figure A.11
Hedgehog signaling pathway Figure A.12
VEGF signaling pathway Figure A.13
ECM-receptor interaction Figure A.14
Cell adhesion molecules (CAMs) Figure A.15
Tight junction Figure A.16
Gap junction Figure A.17
Antigen processing and presentation Figure A.18
Toll-like receptor signaling pathway Figure A.19
Jak-STAT signaling pathway Figure A.20
T cell receptor signaling pathway Figure A.21
B cell receptor signaling pathway Figure A.22
Fc epsilon RI signaling pathway Figure A.23
Insulin signaling pathway Figure A.24
GnRH signaling pathway Figure A.25
Melanogenesis Figure A.26
Adipocytokine signaling pathway Figure A.27
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa03320)
(b) Modeled according KGML information
Figure A.1: PPAR signaling pathway (hsa03320)
146 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04012)
(b) Modeled according KGML information
Figure A.2: ErbB Signalig pathway (hsa04012)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04020)
(b) Modeled according KGML information
Figure A.3: Calcium Signaling pathway
148 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04060)
(b) Modeled according KGML information
Figure A.4: Cytokine-cytokine receptor interaction (hsa04060)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04062)
(b) Modeled according KGML information
Figure A.5: Chemokine signaling pathway (hsa04062)
150 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04080)
(b) Modeled according KGML information
Figure A.6: Neuroactive ligand-receptor interaction (hsa04080)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04115)
(b) Modeled according KGML information
Figure A.7: p53 signaling pathway (hsa04115)
152 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04150)
(b) Modeled according KGML information
Figure A.8: mTOR signaling pathway (hsa04150)
153
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04210)
(b) Modeled according KGML information
Figure A.9: Apoptosis (hsa04210)
154 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04310)
(b) Modeled according KGML information
Figure A.10: Wnt signaling pathway (hsa04310)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04330)
(b) Modeled according KGML information
Figure A.11: Notch Signaling pathway (hsa04330)
156 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04340)
(b) Modeled according KGML information
Figure A.12: Hedgehog signaling pathway (hsa04340)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04370)
(b) Modeled according KGML information
Figure A.13: VEGF signaling pathway (hsa04370)
158 APPENDIX A. MODELED KEGG PATHWAYS
(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04512)
(b) Modeled according KGML information
Figure A.14: ECM-receptor interaction (hsa04512)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04514)
(b) Modeled according KGML information
Figure A.15: Cell adhesion molecules (CAMs) (hsa04514)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04530)
(b) Modeled according KGML information
Figure A.16: Tight junction (hsa04530)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04540)
(b) Modeled according KGML information
Figure A.17: Gap junction (hsa04540)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04612)
(b) Modeled according KGML information
Figure A.18: Antigen processing and presentation (hsa04612)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04620)
(b) Modeled according KGML information
Figure A.19: Toll-like receptor signaling pathway (hsa04620)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04630)
(b) Modeled according KGML information
Figure A.20: Jak-STAT signaling pathway (hsa04630)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04660)
(b) Modeled according KGML information
Figure A.21: T cell receptor signaling pathway (hsa04660)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04662)
(b) Modeled according KGML information
Figure A.22: B cell receptor signaling pathway (hsa04662)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04664)
(b) Modeled according KGML information
Figure A.23: Fc epsilon RI signaling pathway (hsa04664)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04910)
(b) Modeled according KGML information
Figure A.24: Insulin signaling pathway (hsa04910)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04912)
(b) Modeled according KGML information
Figure A.25: GnRH signaling pathway (hsa04912)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04916)
(b) Modeled according KGML information
Figure A.26: Melanogenesis (hsa04916)
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(a) KEGG representation (http://www.genome.jp/kegg-bin/show_
pathway?hsa04920)
(b) Modeled according KGML information
Figure A.27: Adipocytokine signaling pathway (hsa04920)

BChapter
Complete results of CRC data
analysis
Summary results of the analysis of this dataset using Wilcoxon testing can be
consulted in table B.1. Here you can ﬁnd pathways not included in results
section, tables as well as representations.
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Pathway name signiﬁcant/total UP DOWN
PPAR signaling pathway 22/106 3 19
ErbB signaling pathway 13/139 11 2
Calcium signaling pathway 4/20 2 2
Cytokine-cytokine receptor interaction 21/179 19 2
Chemokine signalin pathway 5/43 3 2
Neuroactive ligand-receptor interaction 0/7 0 0
p53 signaling pathway 0/150 0 0
mTOR signaling pathway 0/36 0 0
Apoptosis 0/28 0 0
WNT signaling pathway 12/37 6 6
Notch signaling pathway 0/14 0 0
Hedgehog signaling pathway 0/4 0 0
VEGF signaling pathway 2/10 2 0
ECM-receptorinteraction 10/65 10 0
Cell adhesion molecules 9/43 6 3
Tight junction 2/11 2 0
Gap junction 4/11 4 0
Antigen procesing and presentation 0/6 0 0
Toll-like receptor signaling pathway 0/103 0 0
Jak-STAT signaling pathway 7/7 7 0
T cell receptor signaling pathway 6/24 5 1
B cell receptor signaling pathway 0/10 0 0
Fc epsilon RI signaling pathway 0/7 0 0
nsulin signaling pathway 1/54 1 0
GnRH signaling pathway 0/9 0 0
Melanogenesis 1/8 1 0
Adipocytokine signaling pathway 2/31 0 2
Table B.1: Summary results of colorectal cancer experiment (GSE4107)
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Figure B.1: VEGF signaling pathway results in CRC study
VEGF SIGNALING PATHWAY (hsa04370)
Subpathway p-value FDR p.value UP/DOWN
VEGFA-PTGS2 0.0002 0.0023 UP
VEGFA-NOS3 0.0074 0.0372 UP
Table B.2: VEGF results in colorectal cancer study
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JAK-STAT SIGNALING PATHWAY (hsa04630)
Subpathway p-value FDR p.value UP/DOWN
STAM2-MYC 0.0057 0.0130 UP
STAM2-AKT3 0.0074 0.0130 UP
STAM2-PIM1 0.0031 0.0130 UP
STAM2-CCND1 0.0042 0.0130 UP
STAM2-BCL2L1 0.0310 0.0381 UP
STAM2-SPRED1 0.0381 0.0381 UP
STAM2-SPRY3 0.0381 0.0381 UP
Table B.3: Jak-STAT signaling pathway results in colorectal cancer study
Figure B.2: Jak-STAT signaling pathway results in CRC study
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WNT SIGNALING PATHWAY (hsa04310)
Subpathway p-value FDR p.value UP/DOWN
PORCN-MYC 0.0042 0.019 DOWN
PORCN-JUN 0.0042 0.019 DOWN
PORCN-FOSL1 0.0016 0.019 DOWN
PORCN-CCND1 0.0057 0.019 DOWN
PORCN-PPARD 0.0031 0.019 DOWN
MAP3K7-MYC 0.0042 0.019 UP
MAP3K7-JUN 0.0031 0.019 UP
MAP3K7-CCND1 0.0057 0.019 UP
MAP3K7-PPARD 0.0057 0.019 UP
MAP3K7-MMP7 0.0023 0.019 UP
WNT9A-MAPK8 0.0031 0.019 UP
PORCN-MMP7 0.0159 0.049 DOWN
Table B.4: WNT signaling pathway results in CRC study
Figure B.3: WNT signaling pathway results in CRC study
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PPAR SIGNALING PATHWAY (hsa03320)
Subpathway p-value FDR p.value UP/DOWN
9-cis-Retinoic_acid-CPT1C 0.0000 0.0017 DOWN
9-cis-Retinoic_acid-CPT1C 0.0000 0.0017 DOWN
9(S)-HODE-CPT1C 0.0000 0.0017 DOWN
9-cis-Retinoic_acid-CPT1C 0.0002 0.0048 DOWN
LeukotrieneB4-CPT1C 0.0002 0.0048 DOWN
9-cis-Retinoic_acid-LPL 0.0074 0.0438 UP
9-cis-Retinoic_acid-GK 0.0074 0.0438 DOWN
9-cis-Retinoic_acid-SCD 0.0057 0.0438 DOWN
9-cis-Retinoic_acid-MMP1 0.0057 0.0438 DOWN
9(S)-HODE-GK 0.0074 0.0438 DOWN
9(S)-HODE-SCD 0.0057 0.0438 DOWN
9(S)-HODE-MMP1 0.0057 0.0438 DOWN
9-cis-Retinoic_acid-PLTP 0.0074 0.0438 UP
9-cis-Retinoic_acid-CPT2 0.0057 0.0438 DOWN
9-cis-Retinoic_acid-EHHADH 0.0074 0.0438 DOWN
LeukotrieneB4-PLTP 0.0074 0.0438 UP
LeukotrieneB4-CPT2 0.0057 0.0438 DOWN
LeukotrieneB4-EHHADH 0.0074 0.0438 DOWN
9-cis-Retinoic_acid-APOA2 0.0097 0.0467 DOWN
9-cis-Retinoic_acid-ACAA1 0.0097 0.0467 DOWN
LeukotrieneB4-APOA2 0.0097 0.0467 DOWN
LeukotrieneB4-ACAA1 0.0097 0.0467 DOWN
Table B.5: PPAR signaling pathway results in CRC study
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Figure B.4: PPAR signaling pathway results in CRC study
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ERBB SIGNALING PATHWAY (hsa04012)
Subpathway p-value FDR p.value UP/DOWN
HBEGF-STAT5A 0.0000 0.0033 UP
HBEGF-CAMK2A 0.0000 0.0033 UP
HBEGF-STAT5A 0.0001 0.0039 UP
HBEGF-ABL1 0.0004 0.0124 UP
HBEGF-JUN 0.0005 0.0124 UP
HBEGF-PRKCA 0.0005 0.0124 UP
TGFA-CBLC 0.0008 0.0158 DOWN
HBEGF-ELK1 0.0012 0.0178 UP
TGFA-ABL1 0.0012 0.0178 DOWN
HBEGF-CBLC 0.0016 0.0228 UP
HBEGF-BAD 0.0042 0.0453 UP
HBEGF-CDKN1B 0.0042 0.0453 UP
HBEGF-GSK3B 0.0042 0.0453 UP
Table B.6: ERBB signaling pathway results in CRC study
Figure B.5: ERBB signaling pathway results in CRC study
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CALCIUM SIGNALING PATHWAY (hsa04020)
Subpathway p-value FDR p.value UP/DOWN
CHRM1-ATP2A1 0.0003 0.0053 DOWN
PLCE1-ITPR1 0.0023 0.0229 DOWN
CALML6 NOS1 PHKA1 CHP CAMK4-PDE1A 0.0057 0.0377 UP
CALML6 NOS1 PHKA1 CHP CAMK4-MYLK 0.0097 0.0485 UP
Table B.7: Calcium signaling pathway results in CRC study
Figure B.6: Calcium signaling pathway results in CRC study
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CYTOKINE-CYTOKINE RECEPTOR INTERACTION (hsa04060)
Subpathway p-value FDR p.value UP/DOWN
PDGFB-PDGFRB PDGFRA 0.0000 0.0011 UP
PDGFB-PDGFRB 0.0000 0.0011 UP
PDGFB-PDGFRA 0.0000 0.0014 UP
CXCL12-CXCR4 0.0001 0.0037 UP
TNFSF10-TNFRSF10D 0.0002 0.0067 DOWN
CXCL12-CXCR7 0.0002 0.0067 UP
INHBB-ACVR1 ACVR2A 0.0016 0.0331 UP
INHBB-ACVR2A ACVR1B 0.0016 0.0331 UP
CX3CL1-CX3CR1 0.0023 0.0331 UP
CCL7-CCR1 0.0031 0.0331 UP
CCL5-CCR1 0.0031 0.0331 UP
CCL14-CCR1 0.0031 0.0331 UP
CCL16-CCR1 0.0031 0.0331 UP
CCL23-CCR1 0.0031 0.0331 UP
CCL15-CCR1 0.0031 0.0331 UP
FLT3LG-FLT3 0.0023 0.0331 UP
IL19-IL20RA 0.0023 0.0331 DOWN
INHBE-ACVR1 ACVR2A 0.0042 0.0379 UP
INHBE-ACVR2A ACVR1B 0.0042 0.0379 UP
PDGFA-PDGFRB PDGFRA 0.0042 0.0379 UP
TNFSF13-TNFRSF13B 0.0057 0.0482 UP
Table B.8: Cytokine-Cytokine receptor interaction results in CRC study
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Figure B.7: Cytokine-Cytokine receptor interaction results in CRC study
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CHEMOKINE SIGNALING PATHWAY (hsa04062)
Subpathway p-value FDR p.value UP/DOWN
GRK7-NFKBIA 0.0008 0.0248 UP
CCL26-NFKBIA 0.0012 0.0248 UP
GNB5-NFKBIA 0.0031 0.0451 UP
GNB5-GSK3A 0.0042 0.0456 DOWN
GNB5-FOXO3 0.0057 0.0486 DOWN
Table B.9: Chemokine signaling pathway results in CRC study
Figure B.8: Chemokine signaling pathway results in CRC study
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ECM-RECEPTOR INTERACTION (hsa04512)
Subpathway p-value FDR p.value UP/DOWN
LAMC3-ITGB1 ITGA7 0.0002 0.0074 UP
FN1-ITGAV ITGB8 0.0002 0.0074 UP
RELN-ITGA3 ITGB1 0.0004 0.0077 UP
FN1-ITGA4 ITGB7 0.0016 0.0267 UP
FN1-ITGB1 ITGA5 0.0042 0.0394 UP
FN1-ITGB1 ITGAV 0.0042 0.0394 UP
FN1-G02170 0.0042 0.0394 UP
FN1-ITGA3 ITGB1 0.0057 0.0408 UP
FN1-SDC1 0.0057 0.0408 UP
FN1-ITGA4 ITGB1 0.0074 0.0484 UP
Table B.10: ECM-receptor interaction results in CRC study
Figure B.9: ECM-receptor interaction results in CRC study
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CELL ADHESION MOLECULES (hsa04514)
Subpathway p-value FDR p.value UP/DOWN
NCAM1-NCAM1 0.0001 0.0031 UP
CDH2-CDH2 0.0001 0.0031 UP
L1CAM-CNTN2 L1CAM CNTN2 0.0012 0.0166 UP
CDH2-CDH2 0.0016 0.0177 UP
SELPLG-GLG1 SELE 0.0023 0.0197 UP
PVR-CD226 0.0057 0.0405 UP
HLA-A-CD8A 0.0074 0.0457 DOWN
CD40LG-CD40 0.0097 0.0463 DOWN
CDH2-CDH2 0.0097 0.0463 DOWN
Table B.11: Cell adhesion molecules results in CRC study
Figure B.10: Cell adhesion molecules results in CRC study
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TIGHT JUNCTION (hsa04530)
Subpathway p-value FDR p.value UP/DOWN
RRAS2-MLLT4 0.0057 0.0311 UP
CSNK2A1-OCLN OCLN 0.0031 0.0311 UP
Table B.12: Tight junction results in CRC study
Figure B.11: Tight junction results in CRC study
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GAP JUNCTION (hsa04540)
Subpathway p-value FDR p.value UP/DOWN
DRD1-PRKACA 0.0000 0.0005 UP
ADRB1-PRKACA 0.0001 0.0005 UP
GUCY1A2-PRKG1 0.0057 0.0207 UP
EGF-GJA1 0.0125 0.0343 UP
Table B.13: Gap junction results in CRC study
Figure B.12: Gap junction results in CRC study
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JAK-STAT SIGNALING PATHWAY (hsa04630)
Subpathway p-value FDR p.value UP/DOWN
STAM2-MYC 0.0057 0.0130 UP
STAM2-AKT3 0.0074 0.0130 UP
STAM2-PIM1 0.0031 0.0130 UP
STAM2-CCND1 0.0042 0.0130 UP
STAM2-BCL2L1 0.0310 0.0381 UP
STAM2-SPRED1 0.0381 0.0381 UP
STAM2-SPRY3 0.0381 0.0381 UP
Table B.14: JAK-STAT signaling pathway results in colorectal cancer study
Figure B.13: JAK-STAT signaling pathway results in colorectal cancer study
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T CELL RECEPTOR SIGNALING PATHWAY (hsa04660)
Subpathway p-value FDR p.value UP/DOWN
MAP2K7-FOS 0.0000 0.0003 UP
NCK1 ITK-FOS 0.0001 0.0017 UP
NCK1 ITK-D-myo-Inositol 0.0004 0.0021 UP
NCK1 ITK-CARD11 0.0004 0.0021 UP
NCK1 ITK-IKBKB 0.0005 0.0026 UP
NCK1-PAK4 0.0125 0.0499 DOWN
Table B.15: T cell receptor signaling pathway results in CRC study
Figure B.14: T cell receptor signaling pathway results in CRC study
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Figure B.15: Insulin signaling pathway results in CRC study
INSULIN SIGNALING PATHWAY (hsa04910)
Subpathway p-value FDR p.value UP/DOWN
PRKACA-LIPE 4e-04 0.0193 UP
Table B.16: Insulin signaling pathway results in CRC study
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Figure B.16: Melanogenesis in CRC study
MELANOGENESIS (hsa04916)
Subpathway p-value FDR p.value UP/DOWN
POMC-MITF 0.0057 0.0452 UP
Table B.17: Melanogenesis in CRC study
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Figure B.17: Adipocytokine signaling pathway results in CRC study
ADIPOCYTOKINE SIGNALING PATHWAY (hsa04920)
Subpathway p-value FDR p.value UP/DOWN
TNF-ACSL1 0.0000 0.0004 DOWN
TNF-NPY 0.0012 0.0179 DOWN
Table B.18: Adipocytokine signaling pathway results in CRC study
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Pathway alphaMean alphaVar
Adherens junction 0 0
Measles 0 0
Toll-like receptor signaling pathway 0 0
Vascular smooth muscle contraction 0 0
Viral myocarditis 0
Acute myeloid leukemia 0 0.01
Glutamatergic synapse 0.01 0
Pathogenic Escherichia coli infection 0 0.01
Prostate cancer 0 0.01
Circadian entrainment 0 0.02
Dopaminergic synapse 0.01 0.01
Epstein-Barr virus infection 0 0.02
Salivary secretion 0.01 0.01
Pancreatic secretion 0 0.03
Cell adhesion molecules (CAMs) 0.05 0
Chronic myeloid leukemia 0 0.05
Gap junction 0 0.05
Hepatitis B 0.01 0.04
Shigellosis 0.05 0
Jak-STAT signaling pathway 0 0.06
Hepatitis C 0.01 0.06
Fructose and mannose metabolism 0.02 0.05
Huntington's disease 0.02 0.06
Serotonergic synapse 0.04 0.04
Cholinergic synapse 0 0.09
NF-kappa B signaling pathway 0.01 0.08
Salmonella infection 0.07 0.02
Cell cycle 0 0.1
GABAergic synapse 0.05 0.05
Natural killer cell mediated cytotoxicity 0 0.1
Neuroactive ligand-receptor interaction 0.08 0.02
Nicotinate and nicotinamide metabolism 0.02 0.09
Oocyte meiosis 0.05 0.06
Antigen processing and presentation 0 0.12
Dilated cardiomyopathy 0.01 0.11
Glycerophospholipid metabolism 0 0.12
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HIF-1 signaling pathway 0 0.12
Leukocyte transendothelial migration 0 0.12
Colorectal cancer 0.01 0.12
Inﬂuenza A 0 0.14
Retrograde endocannabinoid signaling 0.03 0.11
Leishmaniasis 0 0.16
Apoptosis 0 0.17
Herpes simplex infection 0 0.18
Gastric acid secretion 0.01 0.18
RIG-I-like receptor signaling pathway 0 0.19
African trypanosomiasis 0.01 0.2
Cocaine addiction 0.04 0.17
Adipocytokine signaling pathway 0 0.22
Long-term depression 0.03 0.19
Osteoclast diﬀerentiation 0.01 0.21
Tight junction 0 0.22
Amyotrophic lateral sclerosis (ALS) 0.05 0.17
Progesterone-mediated oocyte maturation 0.02 0.21
mTOR signaling pathway 0 0.23
Prion diseases 0.01 0.22
Bacterial invasion of epithelial cells 0.01 0.23
Carbohydrate digestion and absorption 0 0.25
Pentose phosphate pathway 0.25 0.03
Glioma 0 0.29
Melanoma 0.02 0.27
Small cell lung cancer 0.02 0.27
B cell receptor signaling pathway 0.03 0.27
Inositol phosphate metabolism 0.04 0.27
ECM-receptor interaction 0 0.33
Bladder cancer 0.04 0.3
Alzheimer's disease 0 0.36
Amino sugar and nucleotide sugar metabolism 0 0.38
Morphine addiction 0.01 0.41
Fc gamma R-mediated phagocytosis 0 0.43
Axon guidance 0 0.46
Insulin signaling pathway 0.01 0.49
Pertussis 0 0.52
Thyroid cancer 0.02 0.52
Wnt signaling pathway 0 0.55
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Fc epsilon RI signaling pathway 0.02 0.57
Glycosphingolipid biosynthesis - lacto and neolacto
series
0.62 0
Neurotrophin signaling pathway 0 0.62
TGF-beta signaling pathway 0 0.63
Toxoplasmosis 0 0.66
Endometrial cancer 0 0.68
NOD-like receptor signaling pathway 0 0.71
Endocrine and other factor-regulated calcium reab-
sorption
0.03 0.71
VEGF signaling pathway 0.05 0.72
ErbB signaling pathway 0 0.92
Table B.19: Signiﬁcant results which came from GraphiteWeb in the CRC
dataset
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Abbreviations
AML Acute Myeloid Leukemia
ASW African Ancestry in Southwest
US
ATM adipose tissue macrophages
AUC area under the curve
BIC Bayesian Information Criterion
CAMDA Critical Assessment of
Massive Data Analysis
CCLE Cancer Cell Line Encyclope-
dia
CEU Utah residents with Northern
and Western-European ancestry
CFS correlation-based feature selec-
tion
CHB Han Chinese in Beijing
CHS Southern Han Chinese
CLM Colombian in Medellin
CPG Cancer Genome Project
CRAN Comprehensive R Archive
Network
CRC colorectal cancer
DNA Deoxyribonucleic acid
DREAM The Dialogue for Reverse
Engineering Assessments and
Methods
FA Fanconi Anemia
FCS Functional Class Scoring
FDR False Discovery Rate
FIN Finnish in Finland
GBR British in England and Scot-
land
GEO Gene Expression Omnibus
Database
HSC hematopoietic stem cells
IBS Iberian populations in Spain
IC50 half-maximal inhibitory con-
centration
IF impact factor
JPT Japanese in Tokyo
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KEGG Kyoto Encyclopedia of Genes
and Genomes
KNN K-Nearest neighbor
KGML KEGG Markup Language
LWK Luhya in Webuye
MCC Mathews correlation coeﬃ-
cient
miRNA microRNA
MM Mismatch probe
mRNA Messenger RNA
MRP masters degree research
project
MXL Mexican Ancestry in Los An-
geles
NCBI National Center for Biotech-
nology Information
ORA Over-Representation Analysis
PANP presence-absence calls with
negative probesets
PBMC peripheral blood mononu-
clear cells
PCC proportion of correct classiﬁca-
tion
PCR Polymerase Chain Reaction
PM Perfect match probe
PolyPhen Polymorphism Phenotyp-
ing
PPI Protein-protein interaction
PUR Puerto Rican in Puerto Rico
RMSE root mean square error
RNA Ribonucleic acid
RNA-seq RNA Sequencing
RP research project
RT-PCR Reverse Trancription PCR
SIF Sorting Intolerant From Tolerant
SNV single nucleotide variation
SVM Support vector machine
TSI Toscani in Italy
TF Transcription Factor
XML Extensible Markup Language
YRI Yoruba in Ibadan
Aminoacids abbreviations:
Ala Alanine
Gin Glutamine
Leu Leucine
Ser Serine
Arg Arginine
Glu Glutamic acid
Lys Lysine
Thr Threonine
Asn Asparagine
Gly Glycine
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Met Methionine
Trp Trytophane
Asp Aspartic acid
His Histidine
Phe Phenylalanine
Tyr Tyrosine
Cys Cysteine
Ile Isoleucine
Pro Proline
Val Valine
